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ABSTRACT	OF	DISSERTATION	
	
	
	
	
			THE	SKELETAL	MUSCLE	MOLECULAR	CLOCK	REGULATES	THE	TIMING	OF	
SUBSTRATE	METABOLISM	AND	THE	CIRCADIAN	EXPRESSION	OF	TITIN-CAP	
	
Skeletal	muscle	is	a	major	contributor	to	whole-body	metabolism	as	it	serves	
as	 a	 depot	 for	 both	 glucose	 and	 amino	 acids,	 and	 is	 a	 highly	metabolically	 active	
tissue.	 An	 intrinsic	molecular	 clock	mechanism	 exists	 within	 skeletal	muscle	 that	
regulates	 the	 timing	 of	 physiological	 processes.	 A	 key	 function	 of	 the	 clock	 is	 to	
regulate	 the	 timing	 of	 metabolic	 processes	 to	 anticipate	 time	 of	 day	 changes	 in	
environmental	conditions.	The	purpose	of	this	study	was	to	identify	metabolic	genes	
that	are	expressed	in	a	circadian	manner	and	determine	if	these	genes	are	regulated	
downstream	 of	 the	 intrinsic	 molecular	 clock	 by	 assaying	 gene	 expression	 in	 an	
inducible	 skeletal	 muscle-specific	 Bmal1	 knockout	 mouse	 model	 (iMS-Bmal1−/−).		
The	 skeletal	muscle	 circadian	 transcriptome	we	 analyzed	was	 highly	 enriched	 for	
metabolic	 processes.	 Acrophase	 (time	 of	 peak	 expression)	 analysis	 of	 circadian	
metabolic	 genes	 revealed	 a	 temporal	 separation	 of	 genes	 involved	 in	 substrate	
utilization	and	storage	over	a	24-h	period	with	many	differentially	expressed	in	the	
skeletal	muscle	of	the	iMS-Bmal1−/−	mice	compared	to	wildtype.		However,	the	iMS-
Bmal1−/−	mice	displayed	circadian	behavioral	 rhythms	 indistinguishable	 from	 iMS-
Bmal1+/+	mice.	We	also	observed	a	gene	signature	indicative	of	a	fast	to	slow	fiber-
type	 shift	 and	 a	more	 oxidative	 skeletal	muscle	 in	 the	 iMS-Bmal1−/−	model.	 These	
data	 provide	 evidence	 that	 the	 intrinsic	 molecular	 clock	 in	 skeletal	 muscle	
temporally	 regulates	 genes	 involved	 in	 the	 utilization	 and	 storage	 of	 substrates	
independent	 of	 circadian	 activity.	 Disruption	 of	 this	 mechanism	 caused	 by	 phase	
shifts	(that	is,	social	jetlag)	or	night	eating	may	ultimately	diminish	skeletal	muscle’s	
ability	to	efficiently	maintain	metabolic	homeostasis	over	a	24-h	period.	
The	 molecular-clock	 targets	 genes	 for	 circadian	 expression	 in	 a	 tissue-
specific	manner,	possibly	through	interactions	with	tissue-specific	factors.		In	order	
to	 identify	novel	mechanisms	responsible	 for	driving	circadian	gene	expression	of	
muscle-specific	genes	we	focused	our	study	on	the	molecular	regulation	of	the	Titin-
cap	 gene.	 	We	 choose	 this	 gene	 as	 it	 was	 highly	 circadian	 in	 the	 skeletal	 muscle	
circadian	 transcriptome,	 and	 has	 previously	 been	 shown	 to	 be	modulated	 by	 the	
clock	 factor	BMAL1	 in	heart-tissue,	 and	 the	myogenic	 regulatory	 factor	MYOD1	 in	
skeletal-muscle.		Promoter-reporter	experiments	demonstrated	that	BMAL1:CLOCK	
and	 MYOD1	 work	 in	 a	 synergistic	 fashion	 to	 transactivate	 the	 Titin-cap	 gene	 in	
skeletal-muscle.	 	Circadian	expression	of	Titin-cap	relied	on	the	normal	function	of	
MYOD1	 as	 mutant	 vectors	 altered	 the	 rhythmic	 oscillation	 and	 expression.	 	 We	
provided	evidence	that	BMAL1	and	MYOD1	bind	to	a	tandem	E-Box	element	in	the	
proximal	 promoter	 element,	 and	 that	 this	 element	 is	 required	 for	 the	 circadian	
expression	of	Titin-cap	in	skeletal-muscle.		These	data	provide	a	novel	mechanism	in	
which	the	molecular-clock	works	with	a	tissue	specific	transcription	factor	to	drive	
circadian	gene	expression.			
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Chapter	1:	Introduction	
Throughout	 the	 history	 of	 life	 on	 Earth,	 organisms	 have	 experienced	 the	 diurnal	
periodicity	 of	 light	 and	 dark	 caused	 by	 the	 axial	 rotation	 of	 the	 Earth	 around	 the	
sun.[1-3]	Pressures	caused	by	daily	oscillations	in	the	environment	have	favored	the	
evolution	 of	 organisms	 that	 have	 adopted	 24-hour	 rhythmic	 cycles,	 or	 circadian	
rhythms.[4-6]	 The	 term	 ‘circadian’	 stems	 from	 the	 Latin	words	 ‘Circa’	 and	 ‘diem’,	
and	can	be	roughly	translated	to	“about	a	day”.		Numerous	circadian	descriptors	are	
commonly	used	to	define	the	patterns	of	these	rhythms,	and	most	common	of	which	
include	 ‘phase’,	 ‘amplitude’,	 and	 ‘period’	 (Figure	 1).[7]	 The	 phase	 of	 the	 rhythm	
denotes	a	particular	 time	within	the	rhythm	and	 is	most	often	associated	with	the	
peak	 or	 highest	 point	 of	 the	 rhythm.	 	 Classically,	 phase	 is	 often	 used	 to	 describe	
‘circadian	time’	(CT)	where	‘CT	0’	denotes	the	beginning	of	the	inactive	period,	while	
‘CT	 12’	 denotes	 the	 beginning	 of	 the	 active	 period.	 	 The	 amplitude	 of	 the	 rhythm	
describes	the	difference	between	the	peak/trough	of	the	rhythm	and	the	calculated	
mean	value.		Typically,	the	amplitude	of	the	rhythm	is	most	often	interpreted	as	the	
strength	 or	 robustness	 of	 the	 rhythm.[8-12]	 Lastly,	 the	 period	 of	 the	 rhythm	
describes	the	length	in	time	it	takes	to	complete	one	full	cycle.[9]			
1.1 Circadian	Rhythms	and	Health	
Growing	evidence	supports	the	association	between	circadian	rhythms	and	human	
health.[13]	 Multiple	 physiological	 processes	 display	 robust	 circadian	 oscillations	
throughout	 the	 day	 and	 include	 fluctuations	 in	 core-body	 temperature,	metabolic	
flux,	 hormone	 release,	 immune	 function,	 sleep-wake	 cycles,	 and	 athletic	
1
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Figure 23.  Representative graph of baseline subtracted T-cap:luciferase 
reporter values with co-transfection of MYOD1 (A) and MYOD1-3Δ56 (B). 
Error bars denoted SEM.  Red circles indicate the co-transfected values.  The 
black circles represents T-cap:luciferase values with no co-transfection.   
Figure 1.  Representative diagram of the circadian descriptors from a 
typical rhythm.   
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performance.[14-19]	 Disruptions	 in	 circadian	 rhythms	 and/or	 mutations	 in	 the	
genes	that	regulate	the	body’s	circadian	clock	have	been	 linked	to	sleep	disorders,	
obesity,	 diabetes,	 psychological	 disorders	 (e.g.	 sleep	 disorders	 and	 bipolar	
disorder),	and	others.[20-25]	Recent	advances	in	circadian	bioinformatics	have	led	
to	 the	 identification	 of	 the	 circadian	 transcriptional	 landscape	 in	 a	 variety	 of	
mammalian	 tissues.	 	These	studies	have	 identified	many	circadian	 transcripts	 that	
encode	 proteins	 that	 are	 known	 drug	 targets.	 	 These	 findings	 suggest	 that	 the	
efficacy	 of	 many	 drugs	 may	 fluctuate	 throughout	 the	 day.[26-28]	 Surprisingly,	
Hogenesch	 et	 al.	 reported	 that	 56	 of	 the	 100	 top-selling	 drugs	 target	 proteins	
encoded	 by	 circadian	 genes.[27]	 Identifying	 ways	 to	 promote	 normal	 circadian	
rhythms	hold	promise	in	treating	disease	and	furthering	human	health.			
1.2 Molecular-Clock	Background	
Circadian	 rhythms	 are	 generated	 by	 an	 intrinsic	molecular	 clock	mechanism	 that	
has	remained	highly	conserved	throughout	evolution,	and	is	present	in	all	most	all	
cellular	 life-forms	 on	 earth	 including	 unicellular	 protozoa,	 insects,	 vertebrates,	
plants,	and	mammals.[29-35]	These	clocks	serve	to	align	behavior	and	physiological	
processes	with	the	rising	and	setting	of	the	sun,	and	thus	allow	organisms	to	more	
efficiently	anticipate,	 and	adapt	 to	environmental	 changes	 (nutritional	 availability,	
predation,	 etc.)	 that	 occur	 throughout	 the	 day.[36]	 A	 fundamental	 component	 of	
circadian	 rhythms	 is	 the	 cell-autonomous	 nature	 in	 which	 they	 exist.	 	 In	 other	
words,	 circadian	rhythms	are	 intrinsic,	and	do	not	require	an	external	stimulus	 to	
provoke	a	response,	as	is	most	often	observed	in	physiological	systems,	but	exist	in	
3
robust	fashion	even	in	the	absence	of	environmental	stimuli.[1,	37,	38]	The	notion	
that	 circadian	 rhythms	 are	 not	 a	 mere	 byproduct	 of	 exogenous	 time-cues	 was	 a	
long-standing	 topic	 of	 debate	 in	 the	 field	 of	 chronobiology,	 originating	 from	what	
some	claim	to	be	the	very	first	circadian	study.		In	1792	a	French	astronomer,	Jean-
Jacques	d’Ortous	de	Mairan,	 found	himself	 very	 interested	 in	 the	heliotrope	plant,	
because	 of	 the	 daily	 opening	 and	 closing	 of	 its	 leaves.[39]	 With	 no	 general	
knowledge	 of	 circadian	 rhythms,	 Mairan	 hypothesized	 that	 the	 leaves	 opened	
everyday	 in	 response	 to	 sunlight.	 	 He	 then	 tested	 this	 idea	 by	 recording	 the	 leaf	
activity	when	the	plant	was	placed	in	constant	darkness.		To	his	surprise,	the	leaves	
opened	 during	 the	 day	 then	 closed	 again	 at	 night	 in	 the	 absence	 of	 light	 cues.		
Mairan	was	not	convinced	that	all	possible	confounding	environmental	factors	were	
properly	controlled	for,	and	suggested	that	 light-leak	was	the	most	 likely	scientific	
explanation.	 	 Chronobiologists	 have	 since	 repeated	 this	 experiment	 with	 proper	
controls,	and	put	to	rest	the	notion	that	circadian	rhythms	are	a	direct	response	of	
exogenous	 time-cues,	 although	 light	and	other	environmental	 cues	help	 to	entrain	
circadian	rhythms.			The	birth	of	modern	molecular	genetic	approaches	and	the	use	
of	 forward-genetic	 screens	 have	 allowed	 investigators	 to	 identify	 the	 molecular	
components	responsible	for	keeping	biological	time	and	has	transformed	the	field	of	
circadian	rhythms.			
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1.2.1 Molecular-Clock	Mechanism	
Circadian	rhythms	in	behavioral	and	physiology	are	generated	by	what	is	commonly	
referred	to	as	the	‘molecular-clock’.[40]	This	machinery	is	genetically	programmed	
within	 the	 majority	 of	 cells	 in	 the	 body,	 and	 exist	 in	 a	 highly	 organized	 and	
hierarchal	manner.[41]	The	master-clock,	 located	in	the	region	of	the	brain	known	
as	 the	 suprachiasmatic	 nucleus	 (SCN),	 processes	 light	 information	 from	 the	
retinohypothalamic	tract	to	synchronize	its	internal	clock	to	the	light:dark	cycle.[42-
44] The	SCN	serves	to	relay	light	information	to	the	clocks	in	the	peripheral	tissues
via	multiple	entrainment	pathways	by	 temporally	 regulating	hormone	release,	 the	
autonomic	 nervous	 system,	 core	 body	 temperature,	 and	 behavior	 (feeding,	
activity).[45]	 In	 effect,	 the	 SCN	 synchronizes	 the	 peripheral	 clocks	 so	 they	 run	 in	
concert,	 and	 loss	of	 a	 functional	 SCN	results	 in	 the	di-synchrony	of	 the	peripheral	
clocks.[46]	The	peripheral	 clocks	 can	 sense	 environmental	 and	 systemic	 cues	 and	
adjust	(i.e.	phase-shift)	their	rhythms	to	temporally	align	with	the	environment.[47]	
For	 instance,	 the	 clocks	 in	 skeletal	 muscle	 can	 be	 entrained	 by	 time	 of	 feeding	
and/or	exercise.	 	Social	 jet-lag,	or	misaligning	the	body’s	 internal	clock	with	social	
time,	 has	 become	 increasingly	 common	 in	 our	 modern	 society	 and	 has	 been	
associated	 with	 detrimental	 health	 effects.[48]	 The	 molecular-clock’s	 ability	 to	
phase-shift	 provides	 additional	 flexibility	 to	 the	 system,	 and	 allows	 organisms	 to	
quickly	 adjust	 to	 alterations	 in	 the	 timing	 of	 the	 external	 light-cycle	 (i.e.	 travel	
across	time	zones).	
The	molecular-clock	mechanism	is	composed	of	two	interconnected	transcriptional-
translational	 feedback	 loops	 that	 generate	molecular	 rhythms	 of	 gene	 expression	
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with	 an	 approximate	 24-hour	 periodicity.[49]	 The	 ‘core-loop’	 is	 composed	 of	 the	
positive-limb	 Period-Arnt-Sim	 (PAS)	 domain	 basic	 helix-loop-helix	 (PAS-bHLH)	
family	 of	 transcription	 factors	 Brain	 and	 Muscle	 Arnt-like	 protein-1	 (Bmal1)	 and	
Circadian	 Locomotor	 Output	 Cycles	 Kaput	 (Clock)	 and	 the	 negative-limb	 Period	
(Per1,2,3)	and	Cryptocrome	(Cry1,2)	gene	families	(Figure	2).[50,	51]	 	BMAL1	and	
CLOCK	 protein,	 oscillate	 in	 a	 circadian	 fashion,	 reach	 peak	 expression	 near	 the	
middle	 of	 the	 inactive	 phase,	 heterodimerize,	 and	 target	 E-box	 elements	 (5’-
CACGTG-3’)	within	the	proximal	promoters	of	the	Per	and	Cry	genes.[52]	Inversely,	
PER	and	CRY	proteins	reach	peak	expression	toward	the	middle	of	the	active	phase,	
heterodimerize,	 and	 inhibit	 BMAL1:CLOCK	 activity.[53]	 Upon	 ubiquitin	 mediated	
degradation	of	PER	and	CRY	proteins	 the	24-hour	 cycle	 is	 complete,	 and	 ready	 to	
begin	again.	The	‘alternative’	interlocking	loop	is	comprised	of	the	Rev-erb	and	Rora	
gene	 families	 that	 are	 also	 targets	 of	 BMAL1:CLOCK.[54,	 55]	When	 REV-ERB	 and	
RORA	 proteins	 reach	 peak	 expression	 they	 target	 Rev-erb	 Response	 Elements	
(ROREs)	 within	 the	 promoters	 of	 the	 Bmal1	 and	 Clock	genes,	 and	 repress	 (REV-
ERBs)	or	activate	(RORAs)	gene	expression.[56,	57]		This	alternative	loop	is	thought	
to	 provide	 stability	 to	 the	 rhythmic	 expression	 of	 Bmal1	 and	 Clock,	 while	 also	
serving	 as	 an	 integrator	 of	 environmental	 information	 (i.e.	 nutrient	 status)	 that	
temporally	aligns	the	clock	to	the	local	environment.		Genetic	disruption	of	the	core	
interlocking	 loop	 genes	 (Bmal1,	Clock,	Per,	Cry)	 results	 in	behavioral	 arrhythmias,	
while	disruption	of	the	alternative	loop	genes	(Rev-erb,	Rora)	alters	the	periodicity	
of	the	rhythm.[49]					
	
6
RORE E-BOX
Bmal1
Clock
BMAL1 CLOCK
REV-ERB’s
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Figure 2. Model of the core and alterative interlocking loops of the molecular 
clock.  BMAL1:CLOCK heterodimers target E-box elements in proximal 
promoter regions of Period and Cryptochrome gene families to drive expres-
sion of the negative limb transcription factors.  Upon transcription/transla-
tions Period and Cryptochrome proteins heterodimerize and translocated 
into the nucleus where they inhibit BMAL1:CLOCK activity at the protein 
level.  BMAL1:CLOCK also drive the expression of the alternative limb com-
posed of the Rev-erb and RORA gene families that target ROREs in the 
promoters of Bmal1 and Clock to repress and activate gene expression, 
respectively.
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1.2.2 Clock-Controlled	Genes	
The	molecular-clock	 temporally	modulates	 gene	 expression	 to	 generate	 a	 protein	
expression	pattern	 that	peaks	at	 a	 single	 time-point	 throughout	a	24-hour	period.		
The	 convergence	 of	 expression	 of	 functionally	 related	 proteins	 ensures	 that	 peak	
rates	 of	 biochemical	 and	 physiological	 processes	 are	 temporally	 aligned	 with	
predictable	 changes	 in	 the	 environment.	 	 Genes	 that	 are	 direct	 targets	 of	 the	
molecular-clock,	but	lack	the	ability	to	modulate	the	timing	mechanism	are	referred	
to	as	 ‘clock-controlled	genes’	(CCG).	 	The	molecular-clock	promotes	circadian	gene	
expression	 through	 multiple	 distinct	 mechanisms.	 	 The	 most	 commonly	 studied	
mechanism	is	the	transactivation	of	genes	by	the	positive-limb	transcription	factors	
BMAL1:CLOCK.	 	 These	 transcription	 factors	 target	 E-box	 elements	 in	 proximal	
promoter	 elements,	 and	 drive	 gene	 expression	 to	 peak	 at	 the	 transition	 from	 the	
inactive	to	active-phase	(~CT	12.0).[58,	59]	Protein	expression	typically	follows	that	
of	 the	 mRNA	 so	 that	 the	 proteins	 encoded	 by	 genes	 directly	 targeted	 by	
BMAL1:CLOCK	 are	 most	 highly	 expressed	 during	 the	 active-phase.	 	 Chromatin-
immunoprecipitation	 sequencing	 (ChIP-Seq)	 studies	 in	peripheral	 tissues	have	 led	
chronobiologists	to	estimate	that	roughly	10%	of	the	actively	transcribed	genes	are	
target	by	BMAL1:CLOCK	in	their	promoter	regions.[60,	61]		Additionally,	substantial	
portions	of	CCGs	are	transcriptional	activators/repressors	themselves	providing	an	
additional	layer	of	circadian	clock	output.	In	addition	to	their	role	in	stabilizing	the	
molecular-clock,	 the	 Rora	 and	 Rev-erb	 gene	 families,	 regulate	 CCGs	 by	 targeting	
ROREs	 in	 the	 promoters	 of	 genes	 to	 rhythmically	 activate	 or	 repress	 gene	
expression,	 respectively.[62]	 REV-ERBs	 have	 an	 important	 role	 in	 regulating	
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metabolic	 timing	 as	 they	 have	 been	 shown	 to	 repress	 lipogenic	 genes	 during	 the	
active-phase.[63,	 64]	 	 By	 repressing	 gene	 express	 during	 the	 active-phase,	 many	
REV-ERB	 targets	 display	 expression	 patterns	 that	 peak	 during	 the	 inactive-phase	
(anti-phasic	 to	 that	 of	 BMAL1:CLOCK	 targets).	 	 Many	 additional	 mechanisms	 of	
clock-output	have	been	observed,	but	will	not	be	discussed	here	as	they	are	outside	
the	scope	of	this	dissertation.		Interestingly,	temporal	gene	expression	experiments	
in	peripheral	tissues	have	revealed	that	the	molecular-clocks	promote	the	circadian	
expression	of	CCGs	in	a	tissue	specific	manner.[41,	61,	65]		It	is	clear	that	the	tissue-
specific	 output	 of	 the	 molecular-clock	 allows	 for	 the	 temporal	 control	 of	 tissue-
specific	 genes	 in	 peripheral	 tissues,	 many	 of	 which	 are	 rate-limiting	 enzymes	 in	
biochemical	pathways,	but	currently	 little	 is	understood	about	the	molecular	basis	
for	this	phenomenon.						
	
1.3 The	Skeletal	Muscle	Molecular-Clock	
Multiple	 studies	 have	 demonstrated	 the	 existence	 of	 a	 robust	 molecular-clock	
mechanism	 in	 skeletal	 muscle.[66-75]	 To	 identify	 genes	 and	 processes	 regulated	
downstream	 of	 the	molecular-clock	 investigators	 have	 studied	 genetic	molecular-
clock	mutant	mouse	models.[60,	 76,	 77]	 Initial	 studies	 relied	 on	 the	 utilization	 of	
“germ-line”	knockout	models	 in	which	core-clock	genes	were	disrupted	or	ablated	
in	every	cell	throughout	the	body.[78-81]	Characterization	of	the	skeletal	muscle	of	
the	 germ-line	 Bmal1	 knockout	 (BMAL1-/-)	 and	 ClockΔ19	 mutant	 mice	 revealed	
significant	 decreases	 in	maximal	 specific-force	 generation	 in	 both	models.[66,	 69,	
74]	The	ClockΔ19	mice	contain	an	antimorphic	mutation	that	results	in	the	deletion	
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of	 exon-19	 of	 the	 Clock	 gene	 that	 encodes	 for	 the	 activation	 domain	 of	 the	
protein.[82]	Electron	microscopy	 imaging	of	 skeletal	muscle	 from	 these	 germ-line	
models	 displayed	 disruptions	 in	 myofilament	 organization,	 suggesting	 a	 possible	
role	of	the	molecular-clock	in	regulating	muscle	structure	and	fuction.[66]	Multiple	
studies	 have	 demonstrated	 that	 Bmal1	 is	 required	 for	 skeletal	 muscle	
development.[83,	 84]	 Interpretation	 of	 the	 phenotypes	 present	 in	 the	 germ-line	
mouse	 models	 is	 troublesome	 since	 these	 mice	 lack	 a	 functional	 molecular-clock	
throughout	all	 tissues,	and	at	all	developmental	 stages.	 	Therefore,	 it	 is	difficult	 to	
discern	whether	the	disruption	of	the	molecular-clock	is	directly	responsible	for	the	
skeletal	 muscle	 phenotypes	 observed	 in	 these	 germ-line	 knockout	 models.	 	 To	
address	 the	confounding	 factors	associated	with	 the	germ-line	knockout	mice,	our	
lab	 and	 others	 have	 recently	 generated	 inducible	 skeletal	 muscle	 specific	 Bmal1	
knockout	mouse	models.	
	
1.4 Scope	of	Thesis:	Part	1	(Chapter	2)		
The	intrinsic	molecular-clock	is	most	known	for	its	role	in	regulating	the	timing	of	
cellular	metabolism	 in	peripheral	 tissues,	 even	under	 constant	 conditions.	 [19-26]	
These	 studies	 have	 shown	 that	 the	 molecular-clock	 temporally	 regulates	 the	
rhythmic	activation	and/or	repression	of	rate-limiting	metabolic	genes	 to	help	 the	
cell	anticipate	changes	in	environmental	conditions	and	metabolic	demand.	[27][85]	
The	 capacity	 of	 the	molecular-clock	 to	 regulate	 metabolism	 is	 highlighted	 by	 the	
metabolic	phenotypes	observed	in	genetic	clock	mutant	models.[63,	64,	81,	86-89]		
The	ClockΔ19	mice	develop	obesity	as	well	as	elevated	blood-glucose	 levels,	while	
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the	Bmal1-/-	mice	display	impairments	in	glucose	handling	and	gluconeogenesis.[90]	
Chip-Seq	analysis	of	REV-ERBα	in	liver	tissue	has	demonstrated	REV-ERBα	binding	
on	 a	 large	 number	 of	 lipid-metabolic	 genes.[91,	 92]	 	 Double	 knockout	 models	 in	
which	Rev-erbα	and	Rev-erbβ	are	ablated	display	disruptions	in	circadian	behavioral	
patterns	 and	 core-clock	 gene	 expression.[92]	 	 The	Rev-erb	 double-knockout	mice	
display	hyperglycemia	and	 increased	 circulating	 triglycerides.	 	 Interestingly,	 these	
mice	display	a	decrease	in	the	respiratory	exchange	ratio	indicative	of	a	shift	from	
carbohydrate	 to	 lipid	 metabolism.[64]	 The	 authors	 suggested	 that	 the	 shift	 in	
metabolism	to	a	more	oxidative-state	was	caused	by	an	increase	in	lipid	metabolic	
gene	expression	due	to	the	loss	of	REV-ERB	mediated	repression.[64]		
Identifying	the	circadian	gene	expression	profile	 in	skeletal	muscle	 is	 fundamental	
to	 understanding	 how	 the	 molecular-clock	 regulates	 physiological	 processes.[45]	
Miller	 et	 al.	 were	 the	 first	 to	 identify	 the	 circadian	 skeletal	 muscle	
transcriptome.[71]	 This	 group	 performed	 a	 time-course	 micro-array	 analysis	 by	
isolating	 RNA	 from	 skeletal	 muscle	 every	 4-hours	 for	 48-hours	 (2	 full	 circadian	
cycles),	 and	 subsequently	 performed	micro-array	 analysis	 at	 each	 time-point.	 	 To	
accurately	 distinguish	 bona	 fide	 circadian	 genes	 from	 that	 of	 outliers	 within	
inherently	 noisy	 time-course	 micro-array	 datasets	 requires	 the	 utilization	 of	
powerful	circadian	statistical	approaches.		Miller	et	al.	used	the	circadian	statistical	
algorithm	known	as	COSOPT	that	fits	temporal	gene	expression	profiles	to	a	cosine	
waveform.		By	comparing	the	temporal	expression	pattern	of	a	circadian	guide	gene	
(e.g.	 Per2),	 Miller	 et	 al.	 established	 a	 ‘goodness	 of	 fit’	 score	 they	 used	 to	 set	 a	
statistical	 cut-off	 for	 identifying	 circadian	 genes.	 	 The	 goodness	 of	 fit	 score	 was	
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calculated	by	employing	a	multiple-measures	corrected-Β	(MMC-β),	and	was	set	to	
MMC-β≤0.2	 for	 this	 study.	 	 267	 genes	 of	 the	 7,824	 genes	 expressed	 in	 wild-type	
(C57Bl6)	 skeletal	 muscle	 were	 identified	 as	 circadian	 (MMC-β≤0.2).	 	 Functional	
gene-ontology	analysis	of	 the	Miller	circadian	muscle	 transcriptome	demonstrated	
that	 the	 largest	 circadian	 gene	 clusters	 included	 genes	 involved	 in	
biosynthesis/metabolism,	 transcriptional	 regulation,	 and	 cell-cycle	 regulation.		
McCarthy	 et	 al.	 were	 the	 next	 group	 to	 generate	 a	 skeletal	 muscle	 circadian	
transcriptome.[70]	Their	experimental	approach	was	very	similar	to	that	of	Miller	et	
al.,	as	they	performed	micro-array	analysis	every	4-hours	for	48-hours	and	used	the	
COSOPT	algorithm	to	identify	circadian	transcripts	in	skeletal	muscle.		In	contrast	to	
Miller	et	al.,	McCarthy	et	al.	considered	transcripts	to	be	circadian	if	they	displayed	a	
20-28	hour	period	 length	and	were	under	 the	 goodness	of	 fit	 score:	MMC-β≤0.15.		
This	analysis	resulted	in	the	identification	of	215	circadian	genes	in	skeletal	muscle.		
Notable	gene-ontology	clusters	 included	regulation	of	protein/lipid	metabolism	as	
well	as	transcriptional	regulation.		Interestingly,	McCarthy	et	al.	identified	a	handful	
of	muscle-specific	circadian	genes	including:	Myod1,	Ucp3,	Atrogin1,	Pdk4,	and	Myh1.	
Andrews	 et	 al.	 validated	 the	 myogenic	 regulatory	 factor,	 Myod1,	 as	 a	 bona	 fide	
BMAL1:CLOCK	target,	providing	additional	evidence	that	the	molecular-clock	plays	
a	role	in	skeletal	muscle	development	and	function.[66]			
These	 initial	 transcriptome	 studies	 provided	 a	 fundamental	 framework	 to	 our	
understanding	 of	 circadian	 gene	 regulation	 in	 skeletal	 muscle,	 but	 vastly	 under-
represented	the	number	of	oscillating	transcripts.		The	circadian	genes	identified	in	
these	studies	amounted	for	only	~3%	of	the	total	skeletal	muscle	transcriptome,	a	
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number	that	is	lower	than	one	would	predict	from	the	BMAL1	ChIP	Seq	studies	(10-
15%	coverage	of	expressed	genes).[60]	This	discrepancy	may	be	explained	by	 the	
technological	and/or	experimental	limitations	of	these	initial	transcriptome	studies.		
The	Miller	and	McCarthy	studies	utilized	gene	arrays	that	are	less	sensitive	than	the	
Affymetrix	 gene	 Chips	 now	 available.	 	 In	 addition,	 these	 groups	 employed	 the	
COSOPT	 statistical	 algorithm	 to	 identify	 circadian	 genes,	 which	 has	 since	 been	
demonstrated	as	less	sensitive	and	specific	for	the	detection	of	rhythmic	transcripts	
in	comparison	to	the	JTK_CYCLE	algorithm.		The	JTK_CYCLE	algorithm	is	a	fusion	of	
two	 powerful,	 non-parametric	 statistical	 tests	 called	 Jonckeere-Tepstra	 (JT)	 and	
Kendall’s	 Tau.	 	 JTK_CYCLE	 employs	 the	 JT	 statistic	 to	 detect	monotonic	 orderings	
within	independent	groups.		This	test	compares	the	expression	at	of	each	circadian	
time-point	in	relation	to	each	other,	and	assigns	a	positive	or	negative	sign.		In	effect,	
a	 matrix	 is	 generated	 for	 each	 microarray	 probset	 depending	 on	 the	 pattern	 of	
expression	throughout	the	experimental	time	series.		Previous	statistical	algorithms,	
such	 as	 COSOPT,	 identify	 rhythmic	 gene	 expression	 by	 curve	 fitting	 the	
experimental	 time-series	 to	 a	 cosine	 waveform.	 	 This	 was	 accomplished	 by	
determining	the	inter-group	differences	between	the	experimental	time-series	and	
the	 cosine	 waveforms.	 	 In	 contrast,	 JTK_CYCLE	 utilizes	 a	 ‘look-up’	 function	 to	
compare	 the	 Kendall’s	 tau	 rank	 correlation	 coefficient	 between	 the	 experimental	
time	series	matrix,	and	the	matrices	from	all	possible	cosine	waveforms	within	the	
range	 of	 user-defined	 period	 lengths.	 	 Through	 the	 use	 of	 the	 Harding	 algorithm,	
JTK_CYCLE	can	rapidly	and	efficiently	determines	the	optimal	combination	of	phase	
and	period	length	that	provides	the	lowest	possible	Kendall’s	Tau	correlation.		Since	
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the	Kendall’s	 tau	depends	only	on	 the	sign	of	 the	 inter-group	differences	between	
circadian	time-points	this	algorithm	is	very	resistant	to	outliers,	and	the	analysis	of	
logarithmically	 transformed	data	 does	 not	 alter	 its	 ability	 to	 efficiently	 determine	
the	optimal	period	 and	phase.	 	 The	 ability	 to	provide	permutation-based	p-values	
and	 q-values	 makes	 JTK_CYCLE	 more	 statistically	 powerful	 and	 computationally	
efficient	 than	 the	 previous	 circadian	 statistical	 algorithms.	 	 Quite	 possibly	 the	
biggest	limitation	of	the	initial	circadian	transcriptome	studies	is	the	low	sampling	
frequency	(every	4-hours	for	48-hours).		The	most	recent	skeletal	muscle	circadian	
transcriptome	generated	by	Hogenesch	et	al.	has	an	improved	statistically	power	for	
the	 detection	 of	 circadian	 transcripts	 due	 to	 a	 doubling	 in	 the	 sampling	
frequency.[27]	Hogenesch	 et	al.	performed	micro-array	 analysis	 every	 2-hours	 for	
48-hours.		As	is	described	in	section	2.2.1	below,	we	employed	the	use	of	JTK_CYCLE	
for	 our	 analysis	 of	 the	 Hodgenesch	 skeletal	 muscle	 transcriptome	 and	 identify	
approximately	1,628	genes	(8x	that	of	the	previous	transcriptomes).[93]			
An	 additional	 benefit	 of	 the	 JTK_CYCLE	 algorithm	 is	 its	 ability	 to	 determine	 the	
acrophase	 of	 each	 circadian	 gene.[94]	 We	 hypothesized	 that	 genes	 involved	 in	
metabolic	processes	 in	skeletal	muscle	would	be	temporally	clustered	over	a	24-hour	
period.	 	 We	 sought	 to	 test	 this	 idea	 by	 identifying	 the	 acrophase	 of	 genes	 with	
common	 ontologies,	 to	 assist	 in	 predicting	 the	 potential	 timing	 of	 metabolic	
processes	in	skeletal	muscle.		As	will	be	shown	in	chapter	2,	the	acrophase	analysis	
of	the	metabolic	genes	within	the	Hogenesch	skeletal	muscle	transcriptome	showed	
that	catabolic	and	anabolic	processes	are	temporally	separated.		To	our	knowledge,	
we	 are	 the	 first	 to	 propose	 an	 in-depth	 molecular	 mechanism	 to	 describe	 how	
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metabolic	processes	are	temporally	regulated.	 	These	findings	will	be	of	particular	
interest	to	the	skeletal	muscle	and	metabolism	fields	since	skeletal	muscle	is	such	a	
large	tissue	and	is	the	main	sight	of	post-prandial	glucose	uptake,	as	well	as	amino-
acid	storage.	
To	further	elucidate	genes	and	physiological	processes	regulated	by	the	molecular-
clock	 many	 investigators	 have	 performed	 transcriptional	 analyses	 of	 peripheral	
tissues	with	genetically	disrupted	clocks.		Miller	et	al.	and	McCarthy	et	al.	performed	
micro-array	analyses	comparing	gene	expression	in	wild-type	and	ClockΔ19	skeletal	
muscle.[70,	 71]	 	 Miller	 et	 al.	 showed	 that	 approximately	 78%	 of	 the	 genes	 they	
identified	 as	 circadian	 displayed	 significantly	 different	 expression	 values	 in	 the	
ClockΔ19	mouse	model	with	the	majority	of	genes	exhibiting	significantly	decreased	
expression.		This	group	did	not	provide	a	detailed	description	of	the	circadian	genes	
that	were	down-regulated	 in	 the	ClockΔ19	 skeletal	muscle,	 although	 they	did	note	
that	 previously	 identified	 CCGs	 such	 as	 Dbp	 and	 Per2	were	 significantly	 down-
regulated.	 	 McCarthy	 et	 al.	 observed	 similar	 findings	 with	 the	 ClockΔ19	 skeletal	
muscle	as	they	reported	changes	in	the	expression	pattern	of	approximately	30%	of	
the	circadian	 transcriptome,	but	do	not	provide	a	detailed	analysis	of	 these	genes.		
Although	these	studies	demonstrate	large	scale	disruptions	of	the	circadian	genes	in	
the	ClockΔ19	 skeletal	muscle,	 it	 is	 now	widely	 accepted	 that	 deletion/mutation	of	
the	 Clock	gene	 does	 not	 completely	 ablate	 molecular	 and	 behavioral	 rhythms	 as	
redundancy	 in	 the	 molecular-clock	 mechanism	 functions	 in	 the	 absence	 of	 the	
CLOCK	 protein.	 	 The	 only	 single	 knockout	 model	 that	 completely	 ablates	 both	
molecular	 and	 physiological	 rhythms	 is	 the	 Bmal1-/-	 knockout	 model.[50]	
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Additionally,	the	use	of	the	ClockΔ19	mouse	model	makes	it	hard	to	discern	whether	
the	transcriptional	changes	observed	in	the	skeletal	muscle	are	truly	caused	by	the	
intrinsic	 molecular-clock	 as	 these	 animals	 lack	 a	 functional	 CLOCK	 protein	
throughout	the	body	and	therefore	display	behavioral	arrhythmias.			
On-going	 studies	 are	 aimed	 at	 utilizing	 organ-specific	 molecular-clock	 mutant	
models	 to	 determine	 the	 function	 of	 the	 clock	 in	 each	 tissue.	 	 These	 studies	 also	
serve	 to	 assess	 the	 role(s)	 the	 peripheral	 clocks	 play	 in	 regulating	 whole	 body	
metabolism	 [39-43].	 	 Dyar	 et	 al.	 have	 recently	 developed	 two	 skeletal	 muscle	
specific	Bmal1	 knockout	models	 to	 study	metabolic	 changes.[68]	 The	 two	models	
consist	of	a	Bmal1	knockout	model	from	birth	(Bmal1flox/flox	x	Mlc1f-Cre),	called	mKO,	
and	a	tamoxifen	 inducible	Bmal1	knockout	model	(Bmal1flox/flox	x	Acta1-Cre),	called	
imKO.	 	 The	mKO	mice	 displayed	 decreases	 in	 specific	 force	 generation	while	 the	
imKO	mice	did	not	 show	any	significant	decrease	 in	 specific	 force	generation,	and	
this	discrepancy	may	be	explained	by	developmental	differences	caused	by	the	loss	
of	 Bmal1	 at	 birth.	 	 This	 group	 demonstrated	 a	 significant	 decrease	 in	 insulin-
stimulated	 glucose	 uptake	 in	 isolated	 soleus	 muscle	 in	 both	 the	 mKO	 and	 imKO	
models	compared	to	age-matched	wildtype	controls	(basal	levels	unaffected).		Dyar	
et	al.	attributed	the	impairments	in	insulin-stimulated	glucose	uptake	to	the	marked	
reduction	in	the	expression	of	the	muscle	specific	glucose	transporter	GLUT4,	and	a	
reduction	 in	 the	 activity	 of	 Pyruvate	 Dehydrogenase	 (PDH)	 responsible	 for	
regulating	 the	 flux	of	 carbohydrates	 into	 the	TCA-cycle.	 	 Since	 the	mKO	and	 imKO	
models	 display	 normal	 circadian	 activity	 patterns,	 the	 impairments	 in	 glucose	
handling	can	be	attributed	to	the	intrinsic	skeletal	muscle	clock.		In	agreement	with	
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the	results	reported	by	Dyar	et	al.,	analysis	of	our	 inducible	muscle	specific	Bmal1	
knockout	model	resulted	 in	circadian	genes	 involved	 in	glucose	and	 lipid	handling	
being	down	and	up-regulated,	respectively.		
	
1.4.1 Scope	of	Thesis:	Part	2	(Chapter	3)	
Previous	studies	have	sought	to	elucidate	the	transcriptional	mechanisms	regulating	
the	Titin-cap	(T-cap)	gene	given	its	functional	importance	in	striated	muscle,	and	its	
roles	 in	Limb-Girdle	muscular	dystrophy	type	2G	and	dilated	cardiomyopathy.[95-
99]	 The	 T-cap	 protein	 forms	 one	 of	 the	 strongest	 known	 non-covalent	 protein-
protein	interactions	in	the	body	through	hydrogen	binding	of	the	Z1-Z2	N-terminal	
domains	of	adjacent	Titin	molecules	to	effectively	link	two	sarcomeres	at	the	Z-line.	
[95]	 T-cap	 is	 highly	 expressed	 in	 both	 skeletal	 muscle	 and	 the	 heart.[98]	 The	
proximal	promoter	region	of	the	T-cap	gene	contains	multiple	E-box	elements	that	
are	highly	conserved	between	humans	and	mice	and	suggests	the	regulation	of	this	
gene	by	bHLH	transcription	factors.[99]	The	myogenic	regulatory	factor	MYOD1	has	
been	shown	to	promote	the	expression	of	T-cap	in	both	porcine	and	mouse	skeletal	
muscle.[97,	99]	 	Podobed	et	al.	showed	that	T-cap	 is	regulated	down-stream	of	the	
molecular-clock	in	mouse	heart	tissue	as	its	mRNA	and	protein	oscillate	in	wild-type	
mice,	 and	 are	 down-regulated	 in	 ClockΔ19	 heart	 tissue.[96]	 This	 group	
demonstrated	 the	 ability	 of	 BMAL1:CLOCK	 to	 promote	 T-cap	 promoter:luciferase	
activity	 and	observed	BMAL1	binding	on	 the	T-cap	 proximal	promoter	at	 a	highly	
conserved	 tandem	 E-box	 element	 (E-box-xxxxxx-E-box).	 	 Further	 analysis	 is	
required	to	determine	if	the	Titin-bound	portion	of	T-cap	oscillates	over	time	of	day.			
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As	stated	earlier,	there	is	a	very	limited	knowledge	of	the	mechanisms	responsible	
for	 tissue-specific	 regulation	of	CCGs.	 	 In	an	attempt	 to	 study	 this	phenomenon	 in	
skeletal	muscle,	we	 sought	 to	 first	 identify	 a	muscle	 specific	CCG	by	performing	 a	
bioinformatics	 analysis	 that	 ultimately	 led	 to	 the	 identification	 of	 T-cap	 as	 a	
circadian	gene	in	skeletal	muscle.	 	Since	previous	studies	have	validated	T-cap	as	a	
BMAL1:CLOCK	target	(heart	tissue)	as	well	as	its	regulation	by	MYOD1,	we	decided	
to	investigate	the	transcriptional	regulation	of	T-cap	as	a	model	for	CCG	regulation	
in	skeletal	muscle.		Our	study	validates	T-cap	as	a	CCG	in	skeletal	muscle	and	reveals	
a	 previously	 unidentified	mechanism	 in	which	MYOD1	works	 synergistically	with	
the	molecular-clock	to	promote	the	circadian	expression	of	T-cap.				
	
2 Chapter	2:	The	endogenous	molecular	clock	orchestrates	the	temporal	
separation	of	substrate	metabolism	in	skeletal	muscle		
Text	and	figures	 in	this	chapter	are	adapted	from	the	first	author	manuscript:	The	
endogenous	 molecular	 clock	 orchestrates	 the	 temporal	 separation	 of	 substrate	
metabolism	in	skeletal	muscle.	Hodge	et	al.,	Skeletal	Muscle	2015.[93]		
	Author	 Contributions:	 BAH	 participated	 in	 the	 time-course	 collection	 and	 RNA	
extraction	 from	 iMS-Bmal1	muscle	 tissue,	 contributed	 to	 the	 recombination	assay,	
carried	out	the	bioinformatics	analysis,	and	drafted	the	manuscript.	YW	participated	
in	 the	 bioinformatics	 analysis,	 contributed	 to	 the	 interpretation	 of	 the	 data,	
generated	the	heat-map,	and	helped	with	the	writing	of	the	manuscript.	LAR	helped	
with	the	bioinformatics	analysis	and	figure	production.	JHE	participated	in	the	time-
course	 collection	 and	preparation	of	 the	RNA	used	 in	 the	microarray	 assays.	BDH	
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and	EAS	participated	in	the	time-course	collection	and	completed	the	mouse	activity	
data	 collection	 and	 analysis.	 EAS	 also	 carried	 out	 the	 real-time	 PCR	 analysis	 and	
participated	 in	 the	 recombination	 assay.	 XZ	 participated	 in	 the	 time-course	
collection	and	performed	the	Western	blot	analysis.	KAE	was	involved	in	the	design	
and	coordination	of	the	study	and	helped	with	the	drafting	of	the	manuscript.		
	
	
2.1 Introduction	
Skeletal	 muscle	 plays	 a	 large	 role	 in	 whole-body	 metabolism	 as	 it	 constitutes	
approximately	 40%	of	 body	mass	 and	 is	 a	 highly	metabolically	 active	 tissue.[100,	
101]	 Basal	 metabolic	 rate	 is	 dependent	 on	 both	 the	 size	 and	 activity	 of	 skeletal	
muscle	as	cross-bridge	cycling	and	calcium	handling	associated	with	contraction	are	
energetically	 expensive	 processes.[101-104]	 Skeletal	 muscle	 is	 a	 principle	
contributor	 to	whole-body	glucose	handling	as	 it	 is	 responsible	 for	 approximately	
80%	 of	 postprandial	 glucose	 uptake.[105,	 106]	 It	 has	 been	 widely	 reported	 that	
skeletal	muscle	has	regulatory	mechanisms	that	modulate	substrate	utilization	and	
storage	 in	 response	 to	 varying	metabolic	 demands	 and	 environmental	 conditions	
(for	example,	nutrient	status).[102,	107-111]	For	instance,	skeletal	muscle	 	rapidly	
modulates	rates	of	glucose	uptake	and	utilization	in	response	to	contraction	and/or	
insulin	stimulation.[112-114]	While	the	fluctuations	in	the	role	for	muscle	to	store	
vs.	use	is	commonly	linked	with	the	fed/fasted	and	active/inactive	behaviors,	these	
changes	 in	 storage	 and	 use	 are	 also	 aligned	 with	 the	 24-h	 (circadian)	 light/dark	
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cycles	 attributed	 to	 the	 rising	 and	 setting	 of	 the	 sun	 and	 feeding/activity	
behavior.[115]	
Utilizing	 high-resolution	 temporal	 transcriptome	 data	 coupled	 with	 circadian	
statistics	has	proved	to	be	an	effective	method	for	identifying	genes	expressed	in	a	
circadian	 manner.[116,	 117]	 In	 the	 present	 study,	 we	 employ	 a	 bioinformatics	
approach	 with	 a	 publically	 available	 high-resolution	 circadian	 data	 set	 collected	
under	 constant	 dark	 conditions	 to	 analyze	 the	 skeletal	 muscle	 circadian	
transcriptome	(gastrocnemius	muscle)	with	a	focus	on	the	temporal	phase	of	gene	
expression.	We	reveal	 that	skeletal	muscle	circadian	genes	are	highly	enriched	 for	
metabolic	 processes,	 and	 furthermore,	 we	 identify	 the	 temporal	 pattern	 of	 peak	
expression	 for	 different	 key	 metabolic	 genes	 separating	 catabolic	 vs.	 anabolic	
processes	 over	 24	 h.	 To	 identify	 which	 circadian-metabolic	 genes	 are	 regulated	
downstream	 of	 the	 intrinsic	 molecular	 clock,	 we	 generated	 an	 inducible	 muscle-
specific	 Bmal1	 knockout	 (iMS-Bmal1−/−)	 mouse	 and	 performed	 a	 time	 series	
transcriptome	 analysis.	 Mice	 lacking	 Bmal1	 in	 skeletal	 muscle	 displayed	 no	
apparent	changes	in	circadian	behavior,	yet	we	observed	significant	decreases	in	the	
expression	 of	 circadian	 genes	 involved	 in	 glucose	 utilization	 and	 adrenergic	
signaling,	while	observing	significant	increases	in	lipogenic	genes.	Consistent	with	a	
substrate	 shift	 from	 carbohydrate	 to	 lipid	 utilization,	 we	 observed	 a	 concomitant	
shift	 from	 a	 fast	 to	 slow	 fiber-type	 gene	 expression	 profile	 indicative	 of	 a	 more	
oxidative	muscle	in	iMS-Bmal1−/−.	These	findings	demonstrate	that	the	endogenous	
molecular	clock	in	skeletal	muscle		contributes	significantly	to	the	time	of	day	shifts	
in	carbohydrate/lipid	metabolism.	
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2.2 Materials	and	Methods	
2.2.1 High-resolution	circadian	microarray	
Microarray	 data	 for	 the	 high-resolution	 circadian	 time-course	 are	 from	
gastrocnemius	 muscles	 of	 male	 C57Bl6	 mice	 collected	 every	 2	 h	 for	 48	 h	 under	
constant	 dark	 conditions	 and	 ad	 libitum	 food	 availability.[27]	 The	 data	 were	
downloaded	 from	 NCBI	 GEO	 datasets	 (GSE54652)	 and	 consist	 of	 24	 individual	
arrays,	 one	 for	 each	 time	 point	 from	 circadian	 time	 18	 to	 64.[117]	 Expression	
intensities	from	the	series	matrix	file	for	all	probesets	at	all	time	points	were	used	
as	 input	 for	 JTK_CYCLE	 analysis,	 with	 period	 length	 set	 to	 24	 h.[94]	 We	 defined	
circadian	 genes	 as	 having	 a	 JTK_CYCLE	 adjusted	 P	 value	 of	 less	 than	 0.05.	 We	
utilized	 the	Bioconductor	package	 to	 identify	mapped	probesets	on	 the	Affymetrix	
Mouse	 Gene	 1.0ST	 chip	 that	 represent	 unique	 genes,	 thus	 eliminating	 control	
probesets	 from	 further	 analyses.	 Genes	 with	 median	 expression	 intensities	 of	 at	
least	 100	were	 considered	 as	 expressed	 in	 skeletal	muscle.	We	entered	 the	 list	 of	
circadian	 genes	 into	 Gene	 Ontology	 Consortium	 online	 tools	 to	 identify	 enriched	
biological	 processes.[118,	 119]	 Enrichment	 P	 values	 were	 adjusted	 for	 multiple	
testing	using	Bonferroni	correction.	
	
2.2.2 Inducible	skeletal	muscle	-specific	Bmal1	inactivation	mouse	model	
All	 animal	 procedures	were	 conducted	 in	 accordance	with	 institutional	 guidelines	
for	 the	 care	 and	 use	 of	 laboratory	 animals	 as	 approved	 by	 the	 University	 of	
Kentucky	 Institutional	 Animal	 Care	 and	 Use	 Committee.	 The	 floxed	Bmal1	 mouse	
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[B6.129S4(Cg)-Arntltm1Weit/J]	was	purchased	 from	The	 Jackson	Laboratory	and	has	
no	 reported	 breeding,	 physical,	 or	 behavioral	 abnormalities.[120]	 The	 skeletal	
muscle-specific	 Cre-recombinase	 mouse,	 [human	 skeletal	 actin	 (HSA)-MerCreMer]	
has	 been	 previously	 characterized.[121]	 The	 floxed	 Bmal1	 mouse	 has	 loxP	 sites	
flanking	exon	8	and	 is	 indistinguishable	 from	wild-type	 littermates.	Breeding	with	
the	 skeletal	 muscle-specific	 Cre-recombinase	 mouse	 generates	 offspring	 in	 which	
selective	deletion	of	 the	bHLH	domain	of	Bmal1	 in	skeletal	muscle	can	be	 induced	
upon	 tamoxifen	administration.	 Inducible	 skeletal	muscle-specific	Bmal1	 knockout	
mice	 were	 generated	 as	 follows:	 the	 Bmal1flox/flox	 female	 was	 crossed	 with	 the	
skeletal	 muscle-specific	 Cre-recombinase	 male.	 This	 yielded	 an	 F1	 generation	 of	
skeletal	muscle-specific	Cre+/−;Bmal1+/flox	mice.	Breeding	the	F1	generation	males	to	
the	Bmal1flox/flox	 females	 resulted	 in	 the	 skeletal	muscle-specific	Cre+/−;Bmal1flox/flox	
mice	(referred	to	as	iMS-Bmal1flox/flox)	needed	for	this	study.	Mouse	genotypes	were	
determined	by	PCR	using	genomic	DNA	 isolated	 from	 tail	 snips.	Activation	of	Cre-
recombination	was	done	by	intraperitoneal	injections	of	tamoxifen	(Sigma-Aldrich,	
St.	Louis,	MO,	USA;	Cat.	No.	T5648)	(2	mg/day)	for	five	consecutive	days	when	the	
mice	reached	12	weeks	of	age.	This	age	was	chosen	to	eliminate	any	effects	that	the	
lack	of	Bmal1	might	have	on	skeletal	muscle	development	and	postnatal	maturation.	
Controls	were	vehicle	(15%	ethanol	in	sunflower	seed	oil)-treated	iMS-Bmal1flox/flox	
mice.	
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2.2.3 Recombination	specificity	
The	 iMS-Bmal1	 mice	 were	 injected	 (intraperitoneal)	 with	 either	 vehicle	 (iMS-
Bmal1+/+)	or	tamoxifen	(iMS-Bmal1−/−)	between	12	and	16	weeks	of	age.	Five	weeks	
postinjection,	 mice	 were	 anesthetized	 with	 isoflurane,	 and	 the	 heart,	 diaphragm,	
liver,	 lung,	 abdominal	 aorta,	 brain,	 tibialis	 anterior,	 soleus,	 gastrocnemius,	 brown	
fat,	white	fat,	and	cartilage	were	collected	and	immediately	frozen	in	liquid	nitrogen	
for	DNA	 analysis.	 Genomic	DNA	was	 extracted	 from	 the	 tissues	 using	 the	DNeasy	
Blood	 and	 Tissue	 Kit	 (Qiagen,	 Venlo,	 Netherlands).	 To	 assess	 recombination	
specificity,	PCR	was	performed	with	tissue	DNA	and	primers	for	the	recombined	and	
non-recombined	alleles	as	described	in	Storch	et	al.[120]	The	forward	and	reverse	
primers	for	the	non-recombined	allele	were	the	same	as	the	genotyping	primers	and	
yielded	 a	 431-bp	 product.	 A	 second	 forward	 primer	 5′-
CTCCTAACTTGGTTTTTGTCTGT-3′	 was	 included	 to	 detect	 the	 recombined	 allele,	
which	showed	a	band	at	572	bp	[50].	The	PCR	reaction	was	run	on	a	1.5%	agarose	
gel	(0.0005%	ethidium	bromide)	to	visualize	the	DNA	products.	
2.2.4 RNA	isolation	and	real-time	PCR	
Total	 RNA	 was	 prepared	 from	 frozen	 gastrocnemius	 tissue	 samples	 using	 TRIzol	
(Invitrogen)	according	to	the	manufacturer’s	directions.	RNA	samples	were	treated	
with	 TURBO	 DNase	 (Ambion,	 Austin,	 TX,	 USA)	 to	 remove	 genomic	 DNA	
contamination.	 Isolated	 RNA	was	 quantified	 by	 spectrophotometry	 (λ	 =	 260	 nm).	
First-strand	 cDNA	 synthesis	 from	 total	 RNA	 was	 performed	 with	 a	 mixture	 of	
oligo(dT)	primer	and	random	hexamers	using	SuperScript	III	First-Strand	Synthesis	
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SuperMix	(Invitrogen,	Waltham,	MA,	USA).	All	isolated	RNA	and	cDNA	samples	were	
stored	 at	 −80°C	 until	 further	 analysis.	 Real-time	 quantitative	 PCR	 using	 TaqMan	
(Applied	 Biosystems,	 Waltham,	 MA,	 USA)	 assays	 was	 used	 to	 examine	 the	 gene	
expression	 of	 Bmal1	 (Mm00500226_m1),	 Rev-erbα	 (Mm00520708_m1),	 Dbp	
(Mm00497539_m1),	 Hk2	 (Mm00443385_m1),	 Pdp1	 (Mm01217532_m1),	 Fabp3	
(Mm02342495),	 and	Pnpla3	 (Mm00504420_m1).	 The	 ΔΔCT	method	was	 used	 for	
the	quantification	of	real-time	PCR	data	in	the	circadian	collections.	
	
2.2.5 Wheel	activity	monitoring	
One	cohort	of	mice	was	used	for	analysis	of	circadian	behavior	(gene	expression	not	
analyzed	in	this	cohort).	A	total	of	20	mice	(mixed	genders)	were	analyzed	with	11	
receiving	tamoxifen	treatment	and	the	remaining	9	receiving	vehicle	treatment.	The	
mice	 were	 maintained	 in	 individual	 cages	 with	 a	 running	 wheel	 under	 12	 L:12D	
(LD)	 conditions	 for	 4	weeks.	 The	wheel	 running	 of	 the	 vehicle	 (iMS-Bmal1+/+)	 or	
tamoxifen	 (iMS-Bmal1−/−)	 mice	 were	 continuously	 recorded	 and	 monitored	
throughout	 the	 experiment	 using	 ClockLab	 software.[122]	 To	 determine	 the	 free-
running	period	of	the	mice,	we	released	them	into	total	darkness	(DD)	for	3	weeks.	
Activity	 was	 evaluated	 using	 voluntary	 running	 wheel	 rotations	 plotted	 in	 1-min	
bins.	 The	 free-running	 period	 (tau)	 during	 the	 3-week	 DD	 period	 was	 calculated	
using	periodogram	analysis	in	the	ClockLab	software.	
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2.2.6 Circadian	collections	
Forty-eight	 iMS-Bmal1flox/flox	 mice	 were	 housed	 in	 individual	 cages	 in	 light	 boxes,	
entrained	 to	 a	 12-h	 LD	 cycle	 for	 14	 days,	 and	 had	 ad	 libitum	 access	 to	 food	 and	
water.	Following	the	2-week	entrainment	period,	24	mice	were	injected	with	vehicle	
and	24	with	tamoxifen	for	five	consecutive	days,	generating	24	iMS-Bmal1+/+	and	24	
iMS-Bmal1−/−	 mice,	 respectively.	 The	 light	 schedule	 was	 kept	 the	 same	 during	
injections	 and	 for	 the	 subsequent	 5	 weeks.	 Five	 weeks	 after	 the	 last	 day	 of	
injections,	mice	were	released	 into	constant	darkness	 for	30	h	 following	protocols	
established	in	the	circadian	field.[27,	70]	Mice	were	sacrificed	in	darkness	(dim	red	
light),	and	skeletal	muscle	s	were	collected	every	4	h	for	20	h	(six	time	points)	and	
frozen	for	RNA	and	protein	analysis.	
2.2.7 Microarray	analysis	of	iMS-Bmal1+/+,	iMS-Bmal1−/−,	and	MKO	(Dyar	et	al.)	
We	 pooled	 equivalent	 amounts	 of	 total	 RNA	 from	 four	 mice	 for	 each	 time	 point	
(circadian	time	18,	22,	26,	30,	34,	38)	and	treatment	(vehicle	or	tamoxifen).	Pooled	
RNA	 samples	 were	 used	 to	 construct	 cDNA	 libraries	 that	 were	 hybridized	 to	
Affymetrix	 Mouse	 Gene	 1.0ST	 microarrays	 (Affymetrix,	 Santa	 Clara,	 CA,	 USA)	 (1	
sample/time	 point).	 Intensity	 data	 for	 iMS-Bmal1+/+	 and	 iMS-Bmal1−/−	
gastrocnemius	muscles	 are	 quantile	 normalized,	 and	 a	 low	 pass	median	 intensity	
filter	 of	 greater	 than	 or	 equal	 to	 100	 is	 applied	 to	 both	 iMS-Bmal1+/+	 and	 iMS-
Bmal1−/−	 datasets	 separately.	 Nine	 thousand	 one	 hundred	 eighty-four	 non-
redundant,	mapped	genes	(9,988	probesets)	are	considered	to	be	expressed	in	one	
or	 both	 datasets.	 Gene	 expression	 changes	 in	 iMS-Bmal1−/−	 muscle	 tissue	 were	
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calculated	 by	 averaging	 the	 change	 in	 expression	 for	 each	 gene	 throughout	 the	
circadian	time	course	(CT18-38,	n	=	6).	Tibialis	anterior	and	soleus	gene	expression	
values	 for	control	and	muscle-specific	knockout	model	(MKO)	 from	Dyar	et	al.[68]	
were	 downloaded	 from	 NCBI	 GEO	 datasets	 (GSE43071)	 and	 consists	 of	 18	
individual	arrays,	three	for	each	time	point	from	circadian	time	0	to	20.	To	compare	
temporal	gene	expression	changes	for	the	TA	and	SOL,	we	averaged	Affymetrix	ST	
1.0	 expression	 values	 for	 each	 gene	 at	 circadian	 times	 0,	 4,	 8,	 12,	 16,	 and	 20.	
Student’s	 t	 test	 was	 used	 to	 identify	 differentially	 expressed	 probesets	 at	 a	
significance	of	P	≤	0.05.	
	
2.2.8 Western	blot	
Whole	cell	lysates	were	prepared	from	the	liver	and	gastrocnemius	of	iMS-Bmal1+/+	
and	 iMS-Bmal1−/−	 mice	 (n	 =	 3/strain).	 SDS-PAGE	 (4-15%	 separating	 gel,	 Bio-Rad,	
Hercules,	 CA,	 USA)	 and	 immunoblotting	 were	 carried	 out	 with	 routine	 protocols.	
Affinity-purified	 Bmal1	 polyclonal	 antibody	 (Sigma-Aldrich,	 SAB4300614)	 was	
visualized	with	IRDye-conjugated	secondary	antibody	using	the	Odyssey	system	(Li-
Cor,	Lincoln,	NE,	USA).	Each	lane	contained	50μg	total	protein.	
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2.3 Results	and	Discussion		
2.3.1 Cellular	metabolic	processes	are	highly	enriched	in	the	circadian	
transcriptome	of	skeletal	muscle		
To	 identify	 circadian	 gene	 expression	 in	 skeletal	 muscle	 ,	 we	 used	 a	 publicly	
available,	 high-resolution,	 circadian	 time-course	 microarray	 dataset	 from	
gastrocnemius	muscles	of	male	C57BL/6	mice.[27,	117]	These	mice	were	housed	in	
constant	darkness,	 and	 food	was	provided	ad	libitum	 to	 eliminate	 the	 influence	of	
external	 environmental	 cues.	 We	 chose	 this	 dataset	 because	 it	 has	 double	 the	
sampling	 frequency	 of	 previously	 published	 circadian	muscle	 transcriptomes,	 and	
this	 allows	 for	 greater	 precision	 for	 circadian	 analysis.[27,	 123]	 Using	 the	
JTK_CYCLE	 statistical	 algorithm	 [94]	 for	 the	 reliable	 detection	 of	 oscillating	
transcripts	with	a	24-h	periodicity,	we	identified	1,628	circadian	mRNAs	(adjusted	P	
<	 0.05).	 An	 unbiased	Gene	Ontology	 enrichment	 analysis	 of	 these	 circadian	 genes	
revealed	 a	 significant	 overrepresentation	 of	 cellular	 metabolic	 processes,	 with	
approximately	 1,004	 (62%)	 genes	 directly	 involved	 in	 skeletal	 muscle	 metabolic	
processes	as	well	as	the	regulation	of	metabolism	(Figure	3).	
Herein,	we	report	the	acrophase	according	to	their	respective	circadian	times	(CT),	
which	 is	 standardized	 to	 the	 free-running	 period	 of	 the	 mice	 under	 constant	
conditions.	For	the	array	studies,	the	mice	were	only	in	DD	for	30	h	so	CT	0	denotes	
the	start	of	the	inactive	period,	while	CT	12	denotes	the	start	of	the	active	period.	To	
identify	the	timing	of	gene	expression	and	its	relationship	to	metabolic	processes	in	
skeletal	muscle,	we	annotated	a	subset	of	circadian	genes	by	their	known	functions,	
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Figure 3.  Gene ontology analysis of the skeletal muscle circadian transcrip-
tome. Top 15 enriched GO processes listed from left to right in order of signi�i-
cance.
28
timing	of	peak	expression,	and	involvement	in	key	metabolic	pathways.	We	focused	
our	analysis	on	metabolic	functions	that	involve	substrate	(carbohydrate	and	lipid)	
utilization	as	well	as	storage	and	biosynthetic	processes.	
2.3.1.1 Lipid	metabolism:	genes	involved	in	fatty-acid	uptake	and	β-oxidation	peak	
in	the	mid-inactive/light	phase	
Skeletal	 muscle	 expresses	 specialized	 membrane	 transporters	 to	 facilitate	 the	
transport	of	lipids	into	the	cell.[124-126]	Two	lipid	transport	genes	that	encode	for	
fatty-acid	binding	proteins,	Fabp4	 (CT	24.0)	and	Fabp3	 (heart/muscle	 isoform,	CT	
6),	 are	expressed	 in	 a	 circadian	manner	with	 the	highest	mRNA	expression	 in	 the	
early-	and	mid-inactive	periods,	respectively.	Acrophase	of	circadian	genes	involved	
in	 lipid	metabolism	 are	 illustrated	 in	 Figure	 4.	 Normalized	 expression	 traces	 for	
each	 gene	 are	 located	 in	 Appendix	 Files	 1	 and	 2.	 Previous	 studies	 have	
demonstrated	 oscillations	 in	 plasma	 fatty	 acid	 concentrations	 in	 mice	 with	 peak	
levels	 occurring	 during	 the	 inactive/light	 period.[92,	 127,	 128]	 Further	 functional	
analysis	 is	 required	 to	 validate	 the	prediction	 that	 the	 rate	of	 fatty-acid	uptake	 in	
skeletal	muscle		peaks	during	the	mid-late	inactive	period.	Upon	uptake	into	the	cell,	
fatty	acids	can	be	stored	as	 triglycerides	or	be	converted	to	acetyl-CoA	through	β-
oxidation.[129]	 Slc25a20	 encodes	 for	 an	 acyl-carnitine	 translocase	 that	 transfers	
fatty	acids	into	the	inner-mitochondrial	matrix	and	reaches	peak	expression	in	the	
middle	of	the	inactive	period	(CT7.5).[130]	We	identified	multiple	genes	that	encode	
for	β-oxidation	enzymes	to	be	circadian	and	also	reach	peak	expression	around	the	
mid-inactive	 phase.	 These	 include	 the	 enoyl	 CoA	hydratase	Ech1	 (CT	7.0),	 the	 tri-
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Figure 4. Schematic acrophase diagram of circadian genes involved in lipid 
metabolic processes. The relative location of the circadian genes(italicized) in 
respect to the x-axis indicates acrophase or time of peak expression calculated 
by the JTK_CYCLE algorithm. Location of substrates and pathways does not 
represent peak substrate concentrations and/or rates of individual pathways 
as these were not measured in our analysis.  White/grey shading is represen-
tative of the inactive and active phases, respectively.
30
functional	enzyme	subunits	Hadha	(CT	8.0)	and	Hadhb	(CT	8.0),	and	the	acetyl-CoA	
acyltransferase	 Acaa2	 (CT	 9.0).	 Malonyl-CoA,	 an	 intermediate	 formed	 during	 de	
novo	 fatty	 acid	 synthesis,	 is	 a	 potent	 inhibitor	 of	 β-oxidation.	 The	 striated	muscle	
enriched	 gene	 Mlycd	 (CT	 7.5)	 encodes	 for	 the	 malonyl-CoA	 decarboxylase	 that	
promotes	 β-oxidation	 by	 reducing	 cytosolic	 concentrations	 of	 malonyl-CoA	 and	
reaches	 peak	 expression	 during	 the	 mid-inactive	 period	 similar	 to	 that	 of	 the	
circadian	 β-oxidation	 genes.	 These	 observations	 suggest	 that	 rates	 of	 β-oxidation	
are	modulated	over	time	of	day	and	potentially	through	the	endogenous	molecular	
clock	in	skeletal	muscle.[109,	131,	132]	
Nuclear	receptors	are	known	to	be	potent	transcriptional	regulators	of	metabolism	
as	they	sense	changes	in	environmental	conditions	and	induce	appropriate	changes	
in	 the	 expression	 of	 metabolic	 genes.[133-137]	 The	 nuclear	 receptor	 Estrogen-
related	 receptor	 alpha	 (Esrra,	 CT	 7.5)	 and	 the	 nuclear	 co-activator	 PPARγ	
coactivartor-1	beta	 (Ppargc1b,	CT	7.0)	are	both	circadian	genes	 in	 skeletal	muscle	
with	peak	expression	occurring	at	the	mid-inactive	phase.	These	factors	have	been	
shown	to	promote	mitochondrial	biogenesis,	fatty-acid	uptake	(targets	Fabp3),	and	
β-oxidation.[138,	139]	The	nuclear	 co-repressor	Nrip1,	 also	known	as	Rip140,	 is	 a	
potent	 negative	 regulator	 of	 skeletal	 muscle	 oxidative	 metabolism	 and	 has	 been	
shown	 to	 suppress	 expression	 of	 the	 fatty-acid	 transporter,	 Fabp3,	 in	 skeletal	
muscle	.[140-142]	NRIP1	suppresses	gene	expression	by	binding	nuclear	receptors	
(including	 PPARs	 and	 estrogen-related	 receptors)	 and	 recruiting	 histone	
deacetylases.[143]	 Interestingly,	 peak	 expression	 of	 Nrip1	 occurs	 during	 the	
beginning	of	the	active	period	(CT	13.0)	and	may	therefore	act	as	a	molecular	brake	
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to	 oxidative	 metabolism	 as	 the	 muscle	 transitions	 from	 lipid	 to	 carbohydrate	
utilization	during	the	early	active	phase.	
2.3.1.2 Lipid	metabolism:	lipogenic	genes	reach	peak	expression	at	the	end	of	the	
active/dark	phase	
The	lipogenic	genes	Acly	(CT23.0),	Acaca	(CT	23.0),	and	Fasn	(CT	22.5)	involved	in	
de	novo	 fatty-acid	 synthesis,	 or	 the	 conversion	 of	 excess	 carbohydrates	 into	 fatty	
acids,	 reach	 peak	 expression	 at	 the	 end	 of	 the	 active	 phase	 (Figure	 4).[129,	 144]	
Scd1	 (CT	 24.0)	 encodes	 the	 enzyme	 that	 catalyzes	 the	 rate-limiting	 reaction	 of	
monounsaturated	 fatty-acid	 formation	 to	 promote	 lipid	 bilayer	 fluidity	 and	
lipogenesis.[145,	146]	The	genes	Srebf1	 (CT	24.5),	Srebf2	 (CT	24.0),	and	Mlxip	 (CT	
23.5)	 encode	 transcription	 factors	 that	 target	 carbohydrate	 response	 elements	
within	 lipogenic	 gene	 promoter	 regions	 (Acly,	 Acaca,	 and	 Fasn)	 and	 are	 also	
circadian	with	peak	expression	at	the	end	of	the	active	phase.[147,	148]	Consistent	
with	 our	 results,	 Srebf1	 oscillations	 have	 been	 reported	 in	 the	 liver	 and	 genome-
wide	binding	studies	have	shown	a	circadian	recruitment	pattern	of	SREBF1	to	the	
promoters	 of	 lipogenic	 genes	 with	 maximal	 binding	 during	 the	 active	 (fed)	
stage.[149-152]	
The	 gene	 Pnpla3	 (CT	 21.0),	 also	 known	 as	 adiponutrin,	 promotes	 lipogenesis	 by	
converting	 LPA	 to	 phosphatidic	 acid	 (PA).[153]	 The	 gene	 Lpin1	 (CT	 24.0)	 which	
encodes	for	the	lipin-1	enzyme	is	responsible	for	converting	phosphatidic	acid	(PA)	
to	diacylglycerol	(DAG),	which	is	the	upstream	metabolite	required	in	phospholipid	
biosynthesis.[154,	 155]	 The	 highly	 regulated,	 committing	 step	 in	 triacylglycerol	
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(TG)	 synthesis,	 addition	 of	 a	 fatty-acyl-CoA	 to	 DAG,	 is	 performed	 by	 the	 product	
encoded	by	Dgat1	 (CT	24.5),	which	 is	 also	 expressed	 in	 a	 circadian	manner.[156]	
Once	a	TG	molecule	is	formed,	it	can	be	elongated	by	enzymes	encoded	by	Acsl5	(CT	
23.0)	or	Elovl5	(CT	22.5).[157,	158]	The	observation	that	circadian	lipogenic	genes	
reach	 peak	 expression	 levels	 around	 the	 end	 of	 the	 active	 phase	 suggests	 that	
skeletal	 muscle	 promotes	 storage	 of	 excess	 energy	 at	 the	 end	 of	 the	
active/absorptive	phase.	
2.3.1.3 Carbohydrate	metabolism:	genes	involved	in	carbohydrate	catabolism	peak	
in	the	early	active/dark	phase	
Glycolysis,	the	breakdown	of	glucose	to	form	pyruvate,	is	primarily	regulated	at	two	
enzymatic	 reactions	 catalyzed	 by	 the	 hexokinase	 and	 phosphofructokinase	
enzymes.[159]	We	observe	that	the	hexokinase-2	(Hk2)	gene	is	circadian	with	peak	
expression	occurring	 at	 the	beginning	of	 the	 active	phase	 (CT	12.0).	Acrophase	of	
circadian	 genes	 involved	 in	 carbohydrate	metabolism	 are	 illustrated	 in	 Figure	 5.	
Normalized	expression	traces	for	each	gene	are	located	in	Appendix	Files	3	and	4.	
Hk2	is	responsible	for	the	first	step	in	glycolysis	by	phosphorylating	glucose	to	make	
glucose-6-phosphate,	 thereby	 trapping	 glucose	 within	 the	 cell.[160]	 The	 rate-
limiting	 step	 of	 glycolysis	 involves	 the	 catalysis	 of	 fructose-6-phosphate	 to	 the	
highly	 unstable	 fructose-1,6-bisphosphate	 by	 the	 enzyme	 phosphofructokinase-1	
(PFKM).[161,	 162]	 A	 potent	 allosteric	 activator	 of	 PFKM	 is	 fructose-2,6-
bisphosphate,	 which	 is	 the	 product	 of	 the	 other	 phosphofructokinase	 isozyme	
phosphofructokinase-2	 (PFK2).[163]	 Three	 genes	 (Pfkfb-1,3,4)	 that	 encode	
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phosphofructokinase-2	 subunits	 are	 circadian	 with	 peak	 expression	 occurring	
during	the	mid-	and	late-inactive	phases	(CT	10.0,	CT	4.5,	and	CT	12.0,	respectively).	
Glycolytic	 flux	 through	 the	 Kreb’s	 cycle	 is	 controlled	 by	 pyruvate	 dehydrogenase	
complex	(PDH).[164,	165]	PDH	decarboxylates	pyruvate	to	form	acetyl-CoA,	which	
is	 a	 substrate	 for	 the	 Kreb’s	 cycle.	 The	 activity	 of	 PDH	 is	 regulated	 at	 the	
posttranslational	 level.	 Phosphorylation	 by	 kinases	 (PDKs)	 inhibits	 PDH	 activity,	
while	dephosphorylation	by	phosphatases	(PDPs)	activates	the	complex.[166,	167]	
The	Pdk4	gene,	which	encodes	for	a	PDH	kinase	that	inhibits	PDH,	reaches	maximal	
expression	at	the	mid-inactive	phase	(CT	6.0).	This	expression	pattern	is	similar	to	
that	of	the	β-oxidation	genes	and	suggests	that	skeletal	muscle	substrate	preference	
is	 pushed	 toward	 utilization	 of	 lipids	 over	 carbohydrates	 during	 the	mid-	 to	 late-
inactive	phase.	Conversely,	the	PDH	phosphatase	gene,	Pdp1,	peaks	at	the	beginning	
of	 the	 active	 phase	 (CT	 10.0)	 in	 a	 similar	 temporal	 fashion	 compared	 to	 the	
glycolytic	enzymes	described	above.	This	temporal	regulation	of	Pdp1	may	therefore	
help	 increase	 glycolytic	 flux	 during	 the	 active	 phase.	 Dyar	 et	al.	 observed	 similar	
expression	patterns	of	Pdk4	and	Pdp1	 in	skeletal	muscle	and	were	first	to	report	a	
shift	to	carbohydrate	utilization	at	the	beginning	of	the	active	phase.[68]	
Adrb2	encodes	for	the	β2-adrenergic	receptor	(β2AR)	involved	in	the	fight-or-flight	
response	in	peripheral	tissues.[168,	169]	Agonist	(that	is,	catecholamine)	binding	is	
well	 established	 to	 evoke	 a	 cell-signaling	 cascade	 that	 promotes	 glucose	 uptake,	
glycogenolysis,	 and	 lipolysis	 to	 provide	 a	 readily	 available	 source	 of	 energy	 for	
skeletal	 muscle.[170-172]	 Adrb2	 is	 expressed	 in	 a	 similar	 pattern	 to	 that	 of	 the	
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glycolytic	 activating	 genes	 as	 it	 peaks	 at	 the	 beginning	 of	 the	 active	 phase.	
Interestingly,	the	expression	of	Adrb2	coincides	with	that	of	oscillating	epinephrine	
concentrations	in	mammals,	which	has	previously	been	identified	as	peaking	at	the	
beginning	of	the	active	phase	in	mouse	models.[173]	The	G-protein	receptor	kinase,	
encoded	 by	Adrbk1,	 phosphorylates	 the	 β2AR,	 thereby	 rendering	 it	 susceptible	 to	
receptor-mediated	 endocytosis	 via	 β-arrestin	 proteins	 encoded	 by	 Arrdc3	 and	
Arrb1.[174-176]	Adrbk1,	Arrdc3,	and	Arrb1	are	all	expressed	in	a	circadian	manner	
and	antiphase	to	the	expression	of	Adrb2.	These	observations	suggest	there	is	a	time	
of	day	difference	in	adrenergic	signaling	and	that	sensitivity	to	epinephrine	may	be	
highest	in	skeletal	muscle	during	the	active	period	while	being	desensitized	prior	to	
the	inactive	period.	
2.3.1.4 Carbohydrate	metabolism:	genes	involved	in	carbohydrate	storage	peak	at	
the	mid-active/dark	phase	
Excess	carbohydrates	are	stored	as	glycogen	in	skeletal	muscle	which	accounts	for	
approximately	 70	 to	 80%	 of	 whole	 body	 stores.[177]	 Unlike	 the	 liver,	 skeletal	
muscle	 glycogen	 content	 is	 not	 responsible	 for	 maintaining	 blood	 glucose	
concentrations	 but	 serves	 as	 a	 rapidly	 accessible	 energy	 depot	 for	 active	
contractions.[170]	Glycogenesis	is	regulated	by	both	glucose-6P	concentrations	and	
the	enzymatic	activity	of	glycogen	synthase.[178,	179]	The	gene	Ppp1r3c	(CT	20.0)	
reaches	 peak	 expression	 around	 the	mid-inactive	 phase	 and	 encodes	 a	 regulatory	
subunit	 of	 the	 protein	 phosphatase-1	 (PP-1)	 responsible	 for	 activating	 glycogen	
synthase	 while	 also	 inhibiting	 glycogen	 breakdown	 (Figure	 5).[180]	 Enzymatic	
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activity	 of	 PP-1,	 and	 subsequent	 activation	 of	 glycogen	 synthase,	 is	 regulated	
downstream	of	the	insulin	signaling	pathway.[181]	
Insulin	promotes	an	anabolic	signaling	cascade	that	works	 in	opposition	to	 that	of	
adrenergic	 signaling	 to	 drive	 glycogen	 and	 lipid	 storage.	 Previous	 reports	 have	
identified	a	 ‘counter-regulatory’	 role	of	 insulin	receptor	 to	selectively	 inhibit	β2AR	
signaling	 through	 phosphorylation	 and	 subsequent	 internalization	 of	 the	
receptor.[169,	 182]	 Interestingly,	 the	 genes	 that	 encode	 the	 insulin	 receptor	
substrate-1,	Irs1	(CT	22.0),	and	its	downstream	PI3-kinase	target,	Pik3r1	(CT	19.0),	
are	both	circadian	with	peak	expression	occurring	at	the	late-active	phase	while	the	
genes	involved	in	suppressing	PI3-kinase,	Pik3ip1	(CT	8.0),	and	the	insulin-receptor	
substrate-1,	Fbxo40	(CT	5.0),	reach	peak	expression	during	the	inactive	phase.[183,	
184]	These	data	suggest	that	the	molecular	clock	may	act	to	prime	skeletal	muscle	
to	 store	 excess	 glucose	 during	 the	 mid-	 to	 late-active	 phase.	 This	 prediction	 is	
further	supported	by	previous	studies	that	report	skeletal	muscle	glycogen	content	
as	having	a	diurnal	rhythm	with	the	highest	levels	occurring	during	the	mid-active	
phase.[185-187]	 Skeletal	 muscle	 glucose	 uptake	 is	 primarily	 controlled	 via	 the	
presence/absence	 of	 the	 glucose	 transporter	 GLUT4/Slc2a4	 in	 the	 plasma	
membrane	(sarcolemma)	and	transverse	tubules.	A	t-SNARE	syntaxin-4	interacting	
protein,	encoded	by	Stxbp4,	has	previously	been	shown	to	repress	GLUT4	insertion	
into	 the	plasma	membrane	 in	 the	absence	of	 insulin	 signaling.[188-190]	The	gene	
Tbc1d1	encodes	for	Rab-GTPase	that	represses	GLUT4	translocation	in	the	absence	
of	 insulin-	 or	 contraction-induced	 signaling	 cascades.[191-193]	 Interestingly,	
Tbc1d1	 and	 Stxbp4	 are	 both	 expressed	 in	 a	 circadian	 manner	 and	 reach	 peak	
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expression	 in	 the	 middle	 of	 the	 active	 phase	 (CT	 19.0).	 Previous	 reports	 have	
identified	Tbc1d1	as	a	circadian	gene	in	skeletal	muscle	and	other	tissues.[68,	194]	
Together,	these	gene	products	may	play	a	role	in	reducing	glucose	uptake	at	the	end	
of	 the	 active	 phase	 by	 repressing	 GLUT4	 translocation	 and/or	 insertion	 into	 the	
plasma	 membrane.	 This	 temporal	 separation	 of	 anabolic	 and	 catabolic	 signaling	
processes	in	skeletal	muscle	may	be	vital	for	maintaining	a	tight	regulation	of	serum	
glucose	levels,	and	disruption	of	which	may	contribute	to	the	metabolic	phenotypes	
often	reported	in	clock-mutant	mice	models.	
2.3.2 Generation	of	an	inducible	skeletal	muscle-specific	mouse	model	of	Bmal1	
inactivation	
Use	 of	 the	 high-resolution	 microarray	 data	 set	 allowed	 for	 the	 identification	 of	
mRNAs	 expressed	 in	 a	 circadian	 pattern,	 but	 this	 could	 be	 due	 to	 the	 intrinsic	
molecular	clock	or	could	be	a	response	to	external	behavioral	(feeding/activity)	or	
neural/humoral	 cues.[195-197]	 To	 determine	 the	 role	 of	 the	 intrinsic	 skeletal	
muscle	molecular	clock	in	the	temporal	regulation	of	metabolic	gene	expression,	we	
generated	 an	 inducible	 mouse	 model	 to	 inactivate	 Bmal1	 specifically	 in	 adult	
skeletal	 muscles.	 Upon	 treatment	 with	 tamoxifen	 in	 12-week-old	 adult	 mice,	 we	
detect	 recombination	 of	 exon-8	 (that	 is,	 DNA	 binding	 region)	 of	 the	 Bmal1	 gene	
specifically	 in	 skeletal	muscle	 (Figure	6A),	 confirming	 the	 tissue	 specificity	of	 the	
mouse	 model.	 We	 waited	 until	 12	 weeks	 of	 age	 to	 limit	 possible	 developmental	
effects	as	BMAL1	has	been	shown	to	promote	myogenesis.[66,	84]	As	seen	in	Figure	
6A,	recombination	was	not	detected	in	the	skeletal	muscle	or	non-muscle	tissues	of	
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Figure 6. Characterization of iMS-Bmal1−/− mice. Recombination assay 
(A) of genomic DNA isolated from muscle and non-muscle tissues from 
tamoxifen-treated (iMS-Bmal1−/−) and vehicle-treated (iMS-Bmal1+/+) 
mice at 17 to 18 weeks of age (5 weeks post-injection). Recombination of 
the Bmal1 gene (exon 8) yields a 572-bp PCR product. The non-recom-
bined allele is detected at 431 bp. Western blot (B) analysis of BMAL1 
expression in iMS-Bmal1−/− and iMS-Bmal1+/+ liver and gastrocnemius 
samples. Note that the original blot containing both muscle and liver sam-
ples was cut, and brightness/contrast was altered to enhance the visibility 
of Bmal1 in the muscle samples. (C) Real-time PCR results of time-course 
expression values for Bmal1, Rev-erbα, and Dbp in the iMS-Bmal1+/+ 
(black) and iMS-Bmal1−/− (red). Representative wheel running rhythms 
(D) of iMS-Bmal1−/− and iMS-Bmal1+/+ mice. White and black bars (top) 
indicate light and dark phases. 12 L/12D represents the 12-h light/12-h 
dark cycle. 12D/12D represents constant darkness conditions. Tick marks 
indicate wheel running activity. Representative chi-squared periodograms 
(E) of iMS-Bmal1−/− and iMS-Bmal1+/+ mice indicating approximate 24-h 
period lengths in both mice.
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vehicle-treated	mice	(iMS-Bmal1+/+).	Western	blot	analysis	confirmed	the	depletion	
of	BMAL1	protein	in	the	skeletal	muscle	of	the	iMS-Bmal1−/−	mice	with	no	effect	on	
the	 liver	 (Figure	 6B).	 Tamoxifen-induced	 loss	 of	 Bmal1	 in	 adult	 skeletal	 muscle		
resulted	 in	 significant	 and	expected	gene	expression	 changes	of	 genes	 involved	 in	
the	 core	 clock	 mechanism.	 In	 particular,	 genes	 directly	 activated	 by	 the	
BMAL1/CLOCK	 heterodimer,	 such	 as	 Rev-erbα	 and	 Dbp,	 are	 markedly	 down-
regulated	 in	 iMS-Bmal1−/−	 but	 not	 in	 the	 iMS-Bmal1+/+	 samples	 (Figure	 6C).	
Collectively,	 these	 results	 demonstrate	 the	 effective	 loss	 of	 BMAL1	 protein	 and	
disruption	of	core-clock	gene	expression	in	the	iMS-Bmal1−/−	muscle	tissue.	
2.3.2.1 iMS-Bmal1-/-	display	normal	circadian	activity	rhythms	
We	 used	 voluntary	wheel	 running	 to	 assess	 circadian	 behavior	 in	 the	 iMS-Bmal1	
mice	22	to	29	weeks	post-treatment.	We	did	not	detect	any	significant	differences	in	
entrainment	 to	 light	under	12-h	 light/12-h	dark	 conditions	between	 iMS-Bmal1+/+	
and	iMS-Bmal1−/−,	and	analysis	of	activity	rhythms	under	constant	darkness	did	not	
reveal	any	changes	in	circadian	behavior	(Figure	6D,	E).	Clock-lab	analysis	indicates	
that	both	 iMS-Bmal1+/+	 and	 iMS-Bmal1−/−	 exhibit	 approximate	24-h	period	 lengths	
(23.85	±	0.083	and	23.77	±	0.138	h,	respectively)	with	no	differences	in	amplitude,	
the	relative	strength	of	the	rhythm.	These	data	are	consistent	with	other	studies	and	
confirm	 that	 inactivation	 of	 BMAL1	 in	 skeletal	 muscle	 does	 not	 directly	 alter	
circadian	activity	patterns.[68,	198]	Therefore,	gene	expression	changes	observed	in	
this	model	 are	more	 likely	 to	 be	 downstream	 of	 the	 endogenous	molecular-clock	
mechanism	in	skeletal	muscle	.	
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2.3.3 Expression	of	key	circadian	metabolic	genes	are	significantly	altered	in	iMS-
Bmal1−/−	skeletal	muscle	
Gene	 expression	 analysis	 of	 iMS-Bmal1+/+	 and	 iMS-Bmal1−/−	 muscle	 tissue	 reveals	
that	 the	 intrinsic	 molecular	 clock,	 even	 in	 constant	 conditions,	 plays	 a	 role	 in	
temporally	 regulating	 carbohydrate	 and	 lipid	 metabolism.	 We	 performed	 our	
transcriptome	 analysis	 at	 5	 weeks	 post-recombination	 to	 identify	 early	 gene	
expression	 changes	 caused	by	 the	 loss	of	 the	 clock	mechanism	 in	 skeletal	muscle.	
Analyzing	gene	expression	at	this	time	point	also	limits	potential	off-target	effects	of	
tamoxifen	treatment	by	allowing	for	a	sufficient	wash-out	period.	We	found	that	the	
circadian	genes	involved	in	carbohydrate	metabolism	were	most	affected	by	loss	of	
Bmal1.	The	expression	of	the	glycolytic	enzymes,	Pfkfb1,	Pfkfb3,	and	Hk2	as	well	as	
the	 PDH	 phosphatase,	 Pdp1	 were	 all	 significantly	 down-regulated	 in	 the	
gastrocnemius	 (Figure	 7A).	 In	 addition,	 expression	 of	 the	 adrenergic	 receptor,	
Adrb2,	was	also	significantly	decreased.	These	genes	are	convincing	clock-controlled	
candidates	in	skeletal	muscle	as	they	have	circadian	expression	patterns	similar	to	
that	 of	 known	 clock-controlled	 genes	 (peak	 expression	 during	 inactive	 to	 active	
phase	 transition),	 and	 their	 loss	 of	 expression	 following	 Bmal1	 inactivation	 is	
indicative	of	direct	transcriptional	regulation	by	the	clock.	By	targeting	these	genes,	
the	molecular	 clock	mechanism	 can	 precisely	 regulate	 the	 timing	 of	 carbohydrate	
utilization	 to	 occur	 during	 the	 active	 phase.	 The	 observation	 that	 circadian	 genes	
involved	in	glucose	utilization	are	diminished	in	our	model	is	in	agreement	with	the	
muscle-specific	Bmal1	knockout	model	generated	by	Dyar	et	al.	in	which	they	report	
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significant	decreases	 in	glucose	oxidation	and	insulin	stimulated	glucose	uptake	 in	
their	muscle	tissues.[68]	
Lipid	metabolic	processes	appear	to	be	elevated	as	the	nuclear	co-repressor,	Nrip1,	
involved	 in	 repressing	 β-oxidation	was	 significantly	 decreased	with	 loss	 of	Bmal1	
(approximately	 21%	 decrease,	 Student’s	 t	 test	P	 value	 =	 0.019).	 Previous	 studies	
have	 shown	 that	 knockout	 of	 Nrip1	 results	 in	 an	 increase	 in	 succinate	
dehydrogenase	 staining	 of	 gastrocnemius	 muscle	 consistent	 with	 a	 shift	 to	 slow	
oxidative	 fiber	 types.[140]	 Interestingly,	 the	 fatty-acid	 transporter,	Fabp3,	 and	 the	
β-oxidation	 genes,	 Hadha	 and	 Hadhb,	 were	 significantly	 elevated	 in	 the	 iMS-
Bmal1−/−	 gastrocnemius	 tissues	 (Figure	 7B).	 Two	 circadian	 genes	 involved	 in	
triacylglycerol	 elongation,	 Pnpla3	 and	 Elovl5,	 were	 also	 increased	 in	 the	 iMS-
Bmal1−/−.	 Altogether,	 we	 report	 significant	 expression	 changes	 in	 circadian	 genes	
that	 are	 key	 regulators	 of	metabolism	 in	 skeletal	muscle.	We	 think	 that	 the	 gene	
changes	 observed	 in	 iMS-Bmal1−/−	 are	 either	 directly	 or	 indirectly	 regulated	
downstream	of	BMAL1/molecular	clock	in	skeletal	muscle	and	not	due	to	changes	in	
external	 cues	 as	 circadian	 activity	 patterns	 in	 iMS-Bmal1−/−	 are	 indistinguishable	
from	 vehicle-treated	 controls.	 The	 observation	 that	 circadian	 genes	 involved	 in	
carbohydrate	 and	 lipid	 metabolism	 are	 disrupted	 in	 iMS-Bmal1−/−	 highlights	 a	
fundamental	 importance	 of	 the	 intrinsic	 molecular	 clock	 in	 temporal	 regulation	
substrate	utilization	and	storage	in	skeletal	muscle	in	the	absence	of	external	cues.	
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2.3.3.1 iMS-Bmal1−/−	gene	expression	changes	reveal	a	fast	to	slow	fiber-type	shift	
Skeletal	muscle	is	comprised	of	different	fiber	types	that	are	differentiated	based	on	
contractile	 function	 as	 well	 as	 predominant	 substrate	 utilization.[199-202]	 For	
example,	fast-type	skeletal	muscle	s	(type	IIX/IIB)	primarily	rely	on	ATP	generated	
from	 anaerobic	metabolism	 (glycolysis/lactic-acid	 fermentation)	 to	 provide	 quick	
energy	 sources	 required	 for	 short	 bursts	 of	 activity,	 while	 slow-type	 skeletal	
muscles	and	fast-type	IIA	muscles	rely	on	oxidative	metabolism	to	promote	a	more	
sustained	 and	 less	 fatigable	 bout	 of	 contractions.	 We	 analyzed	 changes	 in	 gene	
expression	 related	 to	 fiber	 type	 following	Bmal1	 ablation	 in	 adult	 skeletal	muscle	
and	included	both	circadian	and	non-circadian	transcripts.	We	identified	a	selective	
increase	in	slow-type	sarcomeric	genes	in	the	gastrocnemius	muscles	with	a	limited	
effect	on	fast-type	sarcomeric	genes	(Figure	8A,	B).	We	chose	the	list	of	‘slow’	and	
‘fast’	sarcomeric	genes,	because	these	have	been	shown	to	be	significantly	enriched	
in	either	slow-soleus	or	fast-EDL	myofiber	preparations.[203]	Additionally,	calcium	
handling	genes	and	nuclear	receptors	common	in	slow-fiber	muscles	(for	example,	
Casq2,	Atp2a2,	Ankrd2,	Csrp3.)	were	significantly	 increased	in	 iMS-Bmal1−/−	 (Table	
1).	Similar	 to	 the	changes	observed	 for	 the	circadian	metabolic	genes,	we	see	 that	
non-circadian	 metabolic	 genes	 involved	 in	 carbohydrate	 metabolism	 are	
significantly	 decreased,	 while	 genes	 involved	 in	 lipid	 metabolism	 are	 increased	
(Tables	2	and	3).	 This	 switch	 from	a	 fast	 to	 a	 slow	 fiber-type	mRNA	profile	 is	 in	
agreement	 with	 the	 observed	 metabolic	 changes	 as	 slow	 fiber-type	 muscles	 rely	
more	heavily	on	oxidative	metabolism	compared	to	fast-type	skeletal	muscle.	
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Figure 8. Increase in slow type sarcomeric genes in iMS-Bmal1−/−. 
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Gene 
symbol 
Atp2a1
Atp2a2
Calm3
Casq1
Casq2
Itpr1
Pvalb
Ankrd2
Csrp3
Fhl1
Nfatc2
Pdim1
Ppara
Ppargc1
Sos2
Fast or 
slow
Fast
Slow
Fast
Fast
Slow
Fast
Fast
Slow
Slow
Slow
Slow
Slow
Slow
Fast
Fast
Gene 
description
Calcium handling
Calcium handling
Calcium handling
Calcium handling
Calcium handling
Calcium handling
Calcium handling
Nuclear receptor
Nuclear receptor
Nuclear receptor
Nuclear receptor
Nuclear receptor
Nuclear receptor
Nuclear receptor
Nuclear receptor
ΔExpression 
(tam/veh)
0.99
1.06
0.84
1.00
2.89
1.05
1.02
1.66
2.13
1.28
0.88
1.51
1.23
0.83
0.84
Student’s
T-test
ns
ns
***
ns
***
ns
ns
***
**
**
ns
***
*
*
***
Table 1 Fiber-type speci�ic gene expression changes in iMS-Bmal1-/-
Average gene expression changes of calcium handling and nuclear
receptor genes in iMS-Bmal1-/-. ns, non-signi�icant; *≤ 0.01; *** 0.001.≤
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Gene symbol
Agpat3
Acadm
Acot7
Acot9
Acsl1
Cd36
Cox5a
Cox6a1
Cpt2
Fabp1
Fabp5
Fads2
Ldhb
Ndufa8
Ndu�b8
Plin5
Sdhc
Sdhd
Uqcr10
Gene function
Lipogenesis
Lipolysis
Lipolysis
Lipolysis
Lipolysis
Lipid transport
Electron transport chain
Electron transport chain
Lipolysis
Lipid transport
Lipid transport
Lipogenesis
Lactate metabolism
Electron transport chain
Electron transport chain
Lipogenesis
Electron transport chain
Electron transport chain
Electron transport chain
ΔExpression (tam/veh)
1.59
1.31
1.18
1.44
1.24
1.18
1.24
1.30
1.11
1.28
1.29
1.29
1.33
1.24
1.18
1.41
1.18
1.21
1.14
Student’s 
T-test
***
***
***
**
**
**
***
*
*
*
**
*
***
***
**
***
***
**
**
Table 2 Metabolic genes upregulated in iMS-Bmal1-/-
Average gene expression changes of metabolic genes that are signi�icantly
upregulated in iMS-Bmal1-/- skeletal muscle. *P≤0.05; **P≤0.01;***P≤0.001.
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Gene 
symbol
Agl
Akt1
Il15
Pak1
P�km
Pgm2
Phka1
Prkab2
Prkag2
Prkag3
Rab10
Slc2a3
Gene 
function
Glycogenolysis
Glucose uptake
Glucose uptake
Glucose uptake
Glycolysis
Glycogenolysis
Glycogenolysis
Glucose uptake
Glucose uptake
Glucose uptake
Glucose uptake
Glucose uptake
ΔExpression 
(tam/veh)
0.83
0.84
0.86
0.79
0.81
0.87
0.81
0.85
0.83
0.71
0.86
0.35
Student’s 
T-test
***
**
*
*
***
***
**
*
***
**
**
***
Table 3 Metabolic genes downregulated in iMS-Bmal1-/-
Average gene expression changes of metabolic genes that are signi�icantly
downregulated in iMS-Bmal1-/- skeletal muscle. *P≤0.05; **P≤0.01;***P≤0.001.
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2.3.4 Global	Analysis	of	iMS-Bmal1-/-	transcriptome		
The	ablation	of	Bmal1	in	the	iMS-Bmal1-/-	skeletal	muscle	resulted	in	the	large-scale	
disruption	of	circadian	gene	expression	patterns	well	beyond	that	of	the	core-clock	
genes.		The	disruption	in	circadian	rhythmicity	is	visually	apparent	in	the	heat-maps	
of	the	circadian	genes	in	the	iMS-Bmal1+/+	compared	to	iMS-Bmal1-/-	(Figure	9).		
These	maps	were	generated	by	plotting	the	temporal	expression	patterns	of	the	
circadian	genes	in	order	of	their	acrophase.		Due	to	the	limited	time-points	within	
our	transcriptome,	we	were	unable	to	use	JTK_CYCLE	to	statistically	identify	which	
genes	were	circadian	or	not	in	the	iMS-Bmal1-/-.		By	analyzing	the	differential	
expression	of	the	circadian	genes,	we	observed	approximately	297	and	205	genes	
either	significantly	up	or	down-regulated	in	iMS-Bmal1-/-,	respectively.		Phase	
analysis	of	these	genes	revealed	a	temporal	component	to	the	genes	that	were	either	
up	or	down-regulated.		The	majority	of	genes	that	were	down-regulated	in	iMS-
Bmal1-/-	had	a	phase	of	gene	expression	in	wild-type	muscle	around	the	transition	
from	the	inactive	to	active-phase	(Figure	10).		Inversely,	the	majority	of	genes	that	
are	up-regulated	had	a	phase	of	gene	expression	around	the	transition	from	the	
active	to	inactive-phase.		This	unique	pattern	remains	consistent	when	observing	
the	core-clock	gene	changes	in	iMS-Bmal1-/-	as	genes	that	are	known	BMAL1:CLOCK	
targets	with	phases	around	CT	12.0	are	significantly	decreased	(e.g.	Dbp,	Per2,	Rev-
erb,	Rora,	etc.)	(Appendix	File	7).		Interestingly,	three	core-clock	genes	(Clock,	Nfil3,	
and	Npas2)	are	up-regulated	in	the	iMS-Bmal1-/-	tissue	and	reach	peak	expression	in	
an	antiphasic	manner	to	that	of	the	other	core-clock	genes	(~CT	24.0)	(Figure	11).		
Analysis	of	the	gene	expression	profile	in	the	iMS-Bmal1-/-	shows	that	Clock,	Nfil3,	
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Figure 9. Heat-maps of the muscle circadian transcriptome genes in 
iMS-Bmal1+/+ (left) and iMS-Bmal1-/- (right) muscle tissue.  Probsets are 
plotted by phase with high expression in yellow and low expression in blue 
over the circadian time-course from CT 18.0 to 36.0.  
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and	Npas2	are	not	only	up-regulated	at	all	time-points,	but	also	seem	to	flat-line	
which	may	suggest	a	common	upstream	transcriptional	regulator.		Interestingly,	all	
three	of	these	genes	contain	RORE’s	within	their	promoter	regions	and	have	been	
shown	to	be	target	for	repression	by	REV-ERBα	during	the	active	phase.		The	
expression	of	Rev-erbα	is	markedly	decreased	in	the	iMS-Bmal1-/-	as	this	gene	is	a	
direct	BMAL1:CLOCK	target.		The	loss	of	Rev-erbα	expression	in	other	genetic	
models	have	been	shown	to	result	in	a	de-repression	of	REV-ERBα	target	genes	
resulting	in	an	increase	in	their	expression	similar	to	the	up-regulated	circadian	
genes	in	our	analysis.[64,	204]		The	loss	of	Rev-erbα	has	also	been	associated	with	
an	increase	in	an	oxidative	phenotype.[204]	From	these	observations	we	propose	a	
model	in	which	both	limbs	of	the	core-molecular-clock,	BMAL1:CLOCK	and	REV-
ERBα,	function	to	rhythmically	activate	or	repress	gene	expression	during	the	active	
period	(Figure	12).		Further	analysis	involving	a	time-course	ChIP-seq	analysis	for	
both	BMAL1	and	REV-ERBα	would	help	to	further	elucidate	potential	mechanisms.						
2.4 Conclusion	
Here,	 we	 report	 that	 the	 intrinsic	 molecular-clock	 regulates	 the	 timing	 of	 genes	
involved	in	substrate	catabolic	and	anabolic	processes	in	skeletal	muscle.	We	have	
identified	the	mid-inactive	period	as	the	time	of	peak	expression	of	genes	involved	
in	 fatty-acid	 breakdown,	 possibly	 serving	 as	 the	 main	 energy	 source	 to	 skeletal	
muscle	 during	 the	 overnight	 fasting	 period.	 The	 temporal	 expression	 pattern	 of	
genes	that	regulate	glycolysis	and	glycolytic	flux	into	the	TCA’s	cycle	suggests	a	shift	
in	substrate	utilization	during	the	early	active	period	from	lipids	to	carbohydrates,	
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Figure 12. Proposed model demonstrating how BMAL1:CLOCK promote the 
expression of glycolytic genes during the active phase while REV-ERBs 
repress lipogenic genes during the active phase.  Loss of BMAL1 expression 
results in a decrease in the circadian and overall expression of glycolytic 
genes and REV-ERBs resulting in a de-repression of REV-ERB target genes.  
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which	 has	 previously	 been	 documented	 in	 other	 muscle-specific	Bmal1	 knockout	
models.[68]	Genes	involved	in	glucose	and	lipid	storage	were	observed	as	reaching	
peak	expression	toward	the	end	of	the	active	phase,	where	we	predict	excess	energy	
is	 stored	 for	usage	during	 the	post-absorptive	phase.	 Expression	 analysis	 of	 time-
course	data	from	iMS-Bmal1−/−	skeletal	muscle	revealed	the	differential	expression	
of	 a	 number	 of	 key	 circadian	 metabolic	 genes	 in	 the	 absence	 of	 BMAL1.	 These	
findings	 suggest	 that	 the	 temporal	 regulation	 and	 circadian	 rhythmicity	 of	 these	
genes	 is	 directly	 downstream	 of	 the	 intrinsic	 skeletal	 muscle	 molecular-clock	
mechanism.	We	observe	a	gene	expression	profile	that	is	indicative	of	a	glycolytic	to	
oxidative	 fiber	 type	shift	with	 loss	of	Bmal1	 in	adult	muscle	 tissue.	These	 findings	
suggest	 a	 potential	 unidentified	 role	 of	 Bmal1	 in	 the	 maintenance	 of	 fast-type	
muscle	fibers,	possibly	via	direct	transcriptional	regulation	of	glucose	handling.	It	is	
widely	 reported	 that	 aging	 is	 associated	with	 a	 selective	 loss	 of	 fast-type	 skeletal	
muscle	 fibers.[205,	206]	 In	addition,	aging	 is	also	associated	with	decreases	 in	 the	
robustness	of	the	molecular	clock.[69,	207]	These	observations	raise	the	possibility	
that	 fast	 to	 slow	 fiber-type	 shifts	may	 be	 a	 result	 of	 dampening	 of	 the	molecular	
clock	with	 age.	 	 Lastly,	 our	 observations	 from	 the	 temporal	 phase	 analysis	 of	 the	
differentially	expressed	genes	has	led	us	to	propose	a	potential	mechanism	in	which	
the	 molecular-clock	 both	 activates	 and	 represses	 gene	 transcription	 during	 the	
active	phase.				
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3 Chapter	3:	The	molecular-clock	and	MYOD1	promote	the	circadian	expression	of	
Titin-cap	in	skeletal	muscle		
3.1 Introduction	
The	 molecular-clock	 is	 an	 endogenous,	 transcriptional-translational	 feedback	
mechanism	 responsible	 for	 the	 circadian	 regulation	 of	 genes	 and	 physiological	
processes	 in	 peripheral	 tissues.[4-6]	 In	 addition	 to	 its	 vital	 role	 in	 regulating	
metabolism,	 there	 is	 a	 growing	 recognition	 that	 the	 molecular-clock	 plays	
fundamental	roles	in	both	the	development	and	maintenance	of	skeletal	muscle.[66,	
84]	Bmal1	and	 CLOCK	are	 PAS-bHLH	 transcription	 factors	 that	 form	 the	 positive-
limb	of	 the	molecular-clock.[45]	Bmal1,	 in	 particular,	 has	been	 shown	 to	promote	
myogenesis	 via	 the	 activation	 of	 the	 myogenic	 regulatory	 factors	 (MyoD1,	 Myf5,	
Myogenin)	 and	 the	 Wnt-signaling	 cascade.[84]	 Bmal1	 is	 also	 involved	 in	 the	
regeneration	 of	 skeletal	 muscle,	 the	 process	 in	 which	 resident	 satellite	 cells	 are	
activated	 and	 fuse	 to	 form	 new	 muscle.[83]	 The	 myogenic	 and	 regenerative	
functions	 of	Bmal1	 are	 even	more	 so	 apparent	 in	 the	 skeletal	muscle	 phenotypes	
present	 in	Bmal1-/-	and	 include:	 Significant	 decreases	 in	 specific-force	 generation,	
disruptions	 in	 myofibrillar	 organization,	 and	 decreases	 in	 total	 muscle-mass.[66]	
Although	 we	 did	 not	 observe	 significant	 decreases	 in	 muscle	 mass,	 our	 lab	 has	
observed	similar	decreases	in	specific	force	in	an	inducible	skeletal	muscle	specific	
model	suggesting	that	this	effect	 is	 intrinsic	to	the	molecular-clock	in	adult	muscle	
(Manuscript	Submitted	JAP).		
To	 understand	 how	 the	 molecular-clock	 regulates	 skeletal	 muscle	 physiology	
investigators	 have	 sought	 to	 identify	 CCGs	 and	 to	 understand	 the	mechanisms	 in	
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which	 the	 clock	 regulates	 these	 genes.[208-211]	 It	 is	 currently	 unknown	how	 the	
molecular-clock	 targets	 genes	 in	 a	 tissue	 specific	 fashion,	 although	 some	 have	
proposed	 this	 may	 occur	 through	 interactions	 between	 the	 clock	 machinery	 and	
resident	tissue	specific	 factors.[49,	212]	The	validation	of	the	myogenic	regulatory	
factor,	MyoD1,	as	a	direct	target	of	the	molecular-clock	has	raised	the	possibility	that	
oscillations	in	this	protein	could	be	responsible	for	rhythmic	regulation	of	muscle-
specific	processes.	 	Myod1,	along	with	the	other	myogenic	regulatory	 factors	Myf6,	
Myogenin,	 and	 Mrf5	 are	 considered	 ‘master-regulators’	 of	 the	 transcriptional	
program	 that	 promotes	 skeletal	 muscle	 differentiation.[213]	 These	 proteins,	 like	
Bmal1	and	Clock,	are	bHLH	factors	that	homo-	and	heterodimerize	with	themselves	
and	other	transcription	factors	and	bind	to	canonical	E-box	elements	(CANNTG)	to	
promote	myogenic	gene	expression.[214,	215]	 	The	activity	of	MYOD1	to	promote	
gene	expression	depends	on	the	DNA-binding	stability,	 intramolecular	interactions	
that	influence	MYOD1’s	conformation-state,	and	the	presence/absence	of	co-factors	
that	 recruit	 additional	 transcriptional	 machinery	 and/or	 alter	 chromatin	
structure.[216-219]					
In	 the	 present	 study,	 we	 test	 whether	 the	 molecular-clock	 and	 MYOD1	 work	
together	to	promote	the	circadian	expression	of	the	muscle-specific	gene	T-cap.		We	
chose	 T-cap	 as	 a	 model	 gene	 to	 test	 this	 potential	 transcriptional	 mechanism	 in	
skeletal	muscle	as	this	gene	has	previously	been	identified	as	BMAL1:CLOCK	target	
gene	in	heart-tissue,	and	is	activated	by	MYOD1	during	myogenesis.[96,	99]	Using	a	
bioinformatics	 approach	 we	 first	 identify	 T-cap	 as	 a	 circadian	 transcript	 that	 is	
significantly	down-regulated	in	our	iMS-Bmal1-/-	model.	 	We	demonstrate	in	C2C12	
57
muscle-cells	 that	 the	 proximal	 promoter	 of	T-cap	 is	 directly	 targeted	 by	 both	 the	
molecular-clock	and	MYOD1.		Our	study	provides	evidence	of	a	novel	mechanism	in	
which	 that	 molecular-clock	 factors,	 BMAL1:CLOCK,	 work	 cooperatively	 with	 the	
myogenic	regulatory	factor	MYOD1	to	promote	the	circadian	expression	of	T-cap.		
3.2 Materials	and	Methods	
3.2.1 Generation	of	iMS-Bmal1+/+	and	iMS-Bmal1-/-	mice	and	protein	isolation		
Thirty-two	adult	iMS-Bmal1flox/flox	mice	(12-14	weeks	old)	were	treated	with	Vehicle	
or	Tamoxifen	as	described	in	section	2.4.3.		Five	weeks	post	injection	17	tamoxifen	
and	15	vehicle	treated	mice	were	entrained	to	a	12-h	LD	cycle	for	14	days,	and	had	
ad	libitum	access	 to	 food	 and	water.	 	 Following	 the	 entrainment	 period,	 the	mice	
were	euthanized	at	either	CT2	or	CT14	and	gastrocnemius	 tissues	 from	both	hind	
limbs	were	flash	frozen	in	liquid	nitrogen	and	stored	at	-80°C.		Tissues	were	weighed	
and	 homogenized	 mechanically	 in	 RIPA	 buffer	 (40	 w/v)	 containing	 inhibitors	
(Complete	Mini	EDTA-Free	Protease	Inhibitor	from	Sigma	Aldrich,	1%	NaF,	and	1%	
Na-Orthovandate)	on	ice.		Cell-debris	were	pelleted	at	10,000g	for	10	minutes	at	4°C	
and	supernatants	were	quantified	for	protein	concentration	via	Lowry	method.		
3.2.2 Western-blot		
Whole	cell	lysates	were	prepared	from	gastrocnemius	tissue	from	iMS-Bmal1-/-	and	
iMS-Bmal1+/+,	and	liver	lysates	were	prepared	from	wild-type	mice	as	a	negative	
control.		Immunoblotting	were	carried	out	with	routine	protocols.		Briefly,	proteins	
were	denatured	for	5	minutes	at	95°C	in	5x	reducing	buffer.		Approximately	40μg	of	
total	protein	were	added	to	each	well	of	a	SDS-PAGE	gel	containing	a	4%	stacking	
and	12%	running	gel,	and	proteins	were	separated	by	electrical	current.		The	
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proteins	were	then	transferred	to	a	PVDF	membrane	via	a	semi-dry	transfer	
apparatus	(BioRad).		The	membranes	were	placed	in	blocking	solution	(Odyssey)	
for	1	hr.		The	blots	were	then	cut	at	approximately	35Kda,	and	the	bottom	portion	
was	incubated	with	a	monoclonal	Anti-T-CAP	primary	antibody	produced	in	mouse	
at	a	1:200	dilution	(Sigma-Aldrich,	WH0008557M1)	while	the	top	portion	was	
incubated	with	a	polyclonal	Anti-γ-tubulin	primary	antibody	produced	in	mouse	at	a	
1:5000	dilution	(Sigma-Aldrich).		The	primary	antibodies	were	detected	by	goat-
anti-mouse	Alexa	Fluor®	647	secondary	(Abcam150115)	and	visualized	using	the	
Odyssey	system	(Li-Cor,	Lincoln,	NE,	USA).						
3.2.3 RNA	isolation	and	Real-time	PCR		
RNA	was	isolated	from	gastrocnemius	tissue	via	TRIzol	method	and	cDNAs	
prepared	as	described	in	section	2.2.4.	(RNA	samples	prepared	in	the	previous	study	
were	used	for	this	study).		Real-time	quantitative	PCR	was	performed	using	TaqMan	
(Applied	Biosystems,	Waltham,	MA,	USA)	assays	to	determine	the	gene	expression	
of	T-cap	(MM00495557_g1)	and	the	ΔΔCT	method	was	used	for	the	quantification	of	
the	real-time	PCR	data.		The	gene	Rpl26	was	quantified	for	normalization	as	this	
gene	is	highly	expressed	in	skeletal	muscle	and	does	not	oscillate	over	time	of	day.	
3.2.4 Plasmids		
The	T-cap	luciferase	promoter-reporter	construct	was	a	gift	from	Dr.	Davie	from	
Southern	Illinois	University	School	of	Medicine	and	contains	a	421	base	pair	
promoter	fragment	that	spans	from	-421	to	+1	of	the	translational	start	site.[99]	The	
Bmal1	mutant	vector	BMAL1-R91A	was	a	gift	from	Dr.	Takahashi	from	the	
University	of	Texas	Southwestern.		The	MYOD1-3Δ56	construct	was	a	gift	from	Dr.	
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Rudnicki	at	the	Ottawa	Hospital	Research	Institute.		The	control	plasmid	we	used	as	
an	empty	vector	control	was	the	PGEM	vector	from	Promega.		The	wild-type	
expression	vectors	used	in	this	study	include:	MYOD1,	BMAL1,	CLOCK.		In	addition	
to	the	T-cap	reporter,	we	also	used	a	Bmal1:luciferase	reporter	that	contains	the	
Bmal1	promoter	cloned	into	the	pGL3	reporter	vector.			
3.2.5 Site-directed	mutagenesis		
The	QuikChange	Site-Directed	Mutagenesis	Kit	was	used	to	mutate	the	tandem	E-
box	element	in	the	proximal	promoter	region	of	the	T-cap:Luciferase	vector	
according	to	the	manufacturers	instructions.		The	forward	and	reverse	primer	
sequences	are	as	follows:		Reverse-5'-ggcacatgggcagcctgcacccaccttggcactgtc-3',	
Forward-5’-gacagtgccaaggtgggtgcaggctgcccatgtgcc-3'.		The	mutated	T-cap	sequence	
can	be	found	in		Appendix	File	3.		
3.2.6 Dual-Luciferase	Assay	
The	Dual-luciferase	assay	is	commonly	used	to	quantify	the	activity	of	the	reporter	
(Firefly	luciferase),	and	the	co-transfection	control	(Renilla	luciferase).		The	
presence	of	this	internal	control	serves	as	a	baseline	response,	so	variability	due	to	
pipetting	error,	cell	lysis,	or	transfection	efficiency	are	greatly	diminished.		To	study	
the	transactivation	of	T-cap:luciferase	we	performed	transient	co-transfections	of	
the	T-cap:luciferase	promoter-reporter	construct	with	expression	plasmids	in	
C2C12	myoblasts.		For	each	well	of	a	24-well	tissue	culture	plate	we	mixed	50ng	T-
cap:luciferase	reporter,	5ng	pRL	reporter	(Renilla),	and	300ng	each	of	the	
expression	vectors	(MYOD1,	BMAL1,	CLOCK,	BMAL1-R91A,	MYOD-3Δ56)	in	
approximately	0.5mL	of	DMEM	(no	serum)	and	Xtreme-gene9	transfection	reagent	
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5ul/1,000ng	DNA.		The	DNA/transfection	mix	was	then	mixed	with	free-floating	
myoblasts	(50,000/well)	and	plated	with	fresh	GM	(DMEM,	10%FBS,	1%Pen/Strep).		
Each	transfection	was	performed	in	quadruplicate.		GM	was	changed	the	following	
day	and	DM	(DMEM,	2%HS,	1%Pen/Strep)	was	added	at	day	3.		The	cells	were	
differentiated	for	48-h	in	DM	to	form	myotubes.		The	cells	were	lysed	with	5x	
Passive	Lysis	Buffer	(Promega)	for	15	minutes	shaking	at	room-temperature	and	
cell	extracts	were	then	measured	for	Luciferase	and	Renilla	activity	according	to	the	
manufacturer’s	instructions	(Promega).								
3.2.7 Lumicycle		
Co-transfections	were	performed	as	described	in	the	previous	sections	in	C2C12	
myoblasts.		Approximately	150ng	of	T-cap:luciferase	or	Bmal1:luciferase	reporter	
vectors	were	transfected	per	35mm	dish.		Expression	plasmids	or	negative	controls	
(PGEM)	were	co-transfected	with	approximately	500ng	per	35mm	dish.		C2C12	
myoblasts	were	plated	with	the	transfection/DNA	mix	at	300,000	cells	per	35mm	
dish	in	fresh	GM.		After	48-h	the	GM	was	switched	to	DM,	and	the	cells	were	
differentiated	for	5-full	days	(DM	refreshed	every	other	day).		After	differentiation,	
the	myotubes	were	synchronized	with	dexamethasone	(1μΜ)	for	90	minutes,	and	
then	washed	with	PBS	twice	and	1.5mL	of	Recording	buffer	was	added	(DMEM-
Phenol	Red	free,	10mM	HEPES,	luciferin	0.1mΜ,	1%Pen/Strep,	2%	Horse	Serum,	
sodium	bicarbonate	350mg/L).		Cells	were	then	airtight	sealed	and	placed	in	the	
lumicycle	apparatus.		A	32-well	turn-table	is	fully	automated	so	that	the	
photomultiplier	tubes	captured	and	recorded	the	number	of	photons	given	off	by	
each	culture	dish	every	five	minutes.		The	luminometry	data	was	stored	as	photon	
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counts/second	on	a	computer	using	the	lumicycle	software	by	Actimetrix.		
JTK_CYCLE	analysis	was	performed	on	the	lumicycle	data	as	follows:		The	first	1.5	
days	of	recording	was	excluded	to	allow	the	cells	to	equilibrate	fully	after	changes	in	
temperature	and	media	that	occur	during	setup.		We	condensed	the	data	for	ease	of	
handling	and	improved	computational	efficiency	by	binning	data-points	from	every	
5-minutes	to	two	hour	intervals.	The	relative	phase	is	a	measurement	of	the	initial	
peak	following	the	beginning	of	the	analysis	(CT	1.5).			
3.2.8 Chromatin	Immunoprecipitation		
To	determine	binding	of	BMAL1	and	MYOD1	on	the	T-cap	promoter	regions	we	
performed	ChIP	analysis	with	primers	that	scan	the	tandem-E-Box	element	and	
primers	for	the	most	proximal	E-Box	element	on	the	T-cap	promoter.		We	
performed	ChIP	analysis	as	described	in	Andrews	et	al.	2010.[66]		Briefly,	C2C12	
myotubes	were	synchronized	with	1μM	dexamethasone	for	90	minutes	then	
crosslinked	with	1%	formaldehyde	solution	at	room	temperature	for	11	minutes.		
Following	sonication,	the	fragmented	chromatin	was	pre-cleared	with	protein-A/G	
beads	and	then	immunoprecipitated	with	antibodies	against	IgG,	BMAL1	(Abcam),	
and	MYOD1	(Santa-Cruz).		Antibodies	were	then	pulled	down	with	protein-A/G	
beads,	washed,	and	the	DNA	was	eluted	using	the	QIAquick	purification	kit	(Qiagen).		
Quantitative	Real-Time	PCR	(SyberGreen	method)	was	performed	using	DNA	from	
the	input	reaction,	serum,	and	pull-downs	from	IgG,	MYOD1,	and	BMAL1.		Primers	
for	the	T-cap	promoter	are	as	follows:	Tandem-E-Box	element	Forward:5’-
AGCAGAGGAAGACAGTGCCAA-3’,	Reverse:5’-AAGATGCTCTGTTGGGGACCTG-3’;	
proximal	E-Box	element	Forward:5’-CAGGTCCCAACAGAGCATCTT-3’,	Reverse:5’-
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GGGGCTATTTTCAGCCCCTCTG-3’.		Primers	for	the	Myogenin	promoter	were	used	as	
a	positive	control	for	MYOD1	binding,	and	primers	for	the	Period-2	promoter	were	
used	as	a	positive	control	for	BMAL1	binding.		To	visualize	the	qRT-PCR	reaction,	
the	samples	were	run	on	a	4%	stacking,	10%	polyacrylamide	gel,	stained	with	a	
fluorescent	DNA	stain,	and	imaged	with	a	Typhoon	scanner.					
3.2.9 Co-Immunoprecipitation	
To	determine	if	BMAL1	and	MYOD1	bind	in	a	protein:protein	interaction	we	used	
the	Nuclear	Complex	Co-IP	kit	(Active	Motif)	according	to	the	manufacturer’s	
instructions.		To	improve	specificity	and	strength	of	the	pull-down	we	transiently	
transfected	C2C12	myoblasts	with	expression	vectors	for	BMAL1-HA	
(Hemagglutinin)	&	MYOD1,	or	MYOD1-HA	&	BMAL1.		We	performed	the	pull-down	
reactions	with	an	anti-HA	(Sigma	Aldrich)	and	anti-IgG	antibodies.		Western-blots	
were	then	performed	with	antibodies	against	BMAL1	(for	MYOD-HA	pull-down)	or	
MYOD1	(for	BMAL1-HA	pull-down).					
	
3.3 Results	and	discussion		
3.3.1 Circadian	Bioinformatics	 and	 Identification	of	 a	 Candidate	Clock-Controlled	
Gene:	Titin-Cap	(Tcap)		
The	decreases	observed	 in	 specific-force	generation	 in	 the	 skeletal	muscle	of	 iMS-
Bmal1-/-	 mice	 suggests	 that	 the	 molecular-clock	 mechanism	 may	 be	 sufficient	 to	
modulate	the	expression	of	genes	involved	in	muscle	structure	and/or	function.		We	
employed	 a	 circadian	 bioinformatics	 workflow	 to	 determine	 if	 T-cap	 displays	
characteristics	of	a	clock-controlled	gene	in	skeletal	muscle.		Figure	13	outlines	the	
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Figure 13. Schematic of the bioinformatics work�low to identify skeletal 
muscle speci�ic clock-controlled genes.  
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~1,368 genes
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bioinformatics	workflow	that	resulted	 in	 the	 identification	of	T-cap	and	 four	other	
genes	 that	adequately	 fit	our	criteria	as	potential	 skeletal	muscle	specific	CCGs.	 	A	
brief	 description	 of	 our	 analysis	 is	 as	 follows:	 	 To	 identify	 genes	 that	 are	 direct	
targets	 of	 BMAL1:CLOCK	we	 chose	 to	 focus	 on	 circadian	 genes	with	 similar	 gene	
expression	patterns	as	that	of	the	clock-controlled	gene	Dbp.	 	To	do	so	we	utilized	
the	Spearman’s	Rho	rank	correlation	coefficient	test,	which	is	a	non-parametric	test	
commonly	 used	 to	 statistically	 identify	 similar	 patterns.	 	 As	 was	 established	 in	
chapter	 2,	 the	 majority	 of	 known	 BMAL1:CLOCK	 targets	 displayed	 decreases	 in	
overall	 gene	 expression	 in	 the	 iMS-Bmal1-/-	 muscle	 tissue,	 so	 we	 next	 choose	 to	
focus	on	genes	that	are	significantly	decreased	with	loss	of	Bmal1.		At	this	step,	12	of	
the	 68	 genes	 were	 known	 targets	 of	 BMAL1:CLOCK,	 a	 finding	 that	 suggests	 the	
genes	within	 this	 list	are	strong	CCG	candidates.	 	Lastly,	we	choose	 to	 identify	 the	
genes	that	are	highly	enriched	in	skeletal	muscle	yielding	the	5	muscle-specific	CCGs	
including	 T-cap.	 	 Figure	 14	 demonstrates	 the	 circadian	 pattern	 of	 T-cap	 mRNA	
expression	 generated	 from	 the	 Hogenesch	 circadian	 time-course	 microarray.		
JTK_CYCLE	analysis	of	the	T-cap	expression	profile	found	the	transcript	to	be	highly	
statistically	circadian	(p-value:	0.00031).		T-cap	is	one	of	the	most	highly	expressed	
transcripts	in	skeletal	muscle,	and	compared	to	the	circadian	muscle	transcriptome	
its	 expression	 ranks	 in	 the	99th	 percentile.	 	Real-time	PCR	was	performed	 in	 iMS-
Bmal1+/+	 and	 iMS-Bmal1-/-	 muscle-tissue	 (gastrocnemius)	 to	 further	 validate	 the	
oscillation	 of	 T-cap	 mRNA	 that	 was	 observed	 in	 the	 Hogenesch	 time-course	
microarray.	 	We	observed	a	 circadian	gene	expression	pattern	of	T-cap	with	peak	
expression	 occurring	 at	 the	 transition	 from	 inactive	 to	 active-phases	 in	 the	 iMS-
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Figure 14. Temporal expression pattern of T-cap from the Hogenesch 
skeletal muscle circadian transcriptome.  The black circles represent the 
expression values of T-cap at each circadian time-point.  The dotted line is a 
6-degree polynomial �itted to the T-cap expression data.  Grey bars indicat-
ed the active period, and white bars indicate the inactive period. Note that 
mice were in constant darkness during the time-course collection.
JTK_CYCLE p-value 0.00031, period 24h, phase CT12. 
66
Bmal1+/+	 muscle	 (Figure	 15).	 	 The	 temporal	 expression	 pattern	 of	 T-cap	 is	
indicative	 of	 a	 BMAL1:CLOCK	 down-stream	 target	 gene	 as	 direct	 CCGs	 typically	
reach	peak	expression	in	an	anti-phasic	manner	to	that	of	Bmal1.		These	findings	are	
in	 agreement	 with	 that	 of	 T-cap’s	 circadian	 expression	 profile	 that	 has	 been	
documented	in	heart-tissue.	[96]	As	expected,	the	circadian	expression	pattern	of	T-
cap	was	 completely	 abolished	 in	 the	 iMS-Bmal1-/-	muscle	 tissue.	 	 Additionally,	 the	
overall	gene	expression	of	T-cap	was	reduced	on	average	~66%.		Since	the	activity	
pattern	of	iMS-Bmal1-/-	mice	is	indistinguishable	from	that	of	the	controls,	we	argue	
that	T-cap	expression	is	regulated	downstream	of	the	molecular-clock,	and	that	the	
observed	expression	changes	are	caused	by	the	loss	of	Bmal1	in	skeletal	muscle.			
3.3.2 T-cap	is	circadian	in	wild-type	skeletal	muscle		
Although	 circadian	 transcriptome	 analyses	 are	 very	 accurate	 at	 identifying	
oscillatory	 transcripts,	 it	 is	 becoming	 increasingly	 evident	 in	 the	 field	of	 circadian	
rhythms	that	protein	expression	does	not	always	mirror	that	of	the	transcript	so	we	
quantified	 T-CAP	 protein	 expression	 over	 time.	 	 Western-blot	 analysis	 of	 T-CAP	
from	 wild-type	 skeletal	 muscle	 (gastrocnemius)	 demonstrates	 the	 circadian	
oscillation	of	T-CAP	protein	with	peak	expression	occurring	during	the	early	active-
phase	 (Figure	16).	 	The	 finding	 that	T-CAP	oscillates	at	 the	protein	 level	 suggests	
that	the	relative	T-CAP	protein	content,	at	any	given	circadian	time,	may	be	directly	
proportional	to	the	relative	amount	of	T-cap	transcript	levels.		T-CAP	protein	levels	
seem	to	follow	the	mRNA	expression	pattern	with	a	slight-lag,	which	is	typical	of	a	
circadian	gene.		These	observations	do	not	however	discount	the	possibility	that	T-
CAP	 protein	 expression	 may	 also	 be	 temporally	 modulated	 by	 post-translational	
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Figure 15. T-cap real-time PCR results of time-course expression values in 
the iMS-Bmal1+/+ (black) and iMS-Bmal1−/− (red).  Fold difference was 
calculated from control, Rpl-26 Real-Time PCR for each time-point.  Grey bars 
indicated the active period, and white bars indicate the inactive period. Mice 
were in constant darkness during the time-course collection.
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mechanisms.		T-CAP	is	among	a	handful	of	sarcomeric	proteins	ubiquitinated	by	the	
muscle-specific	E3-ubiquitin	ligase,	MURF1	(Trim63)	and	is	targeted	for	degradation	
by	the	26S	proteasome.[220]	Interestingly,	we	found	that	Trim63/Murf1	is	circadian	
in	skeletal	muscle	 	 (p-value	0.0024),	and	 is	expressed	 in	an	anti-phasic	manner	 to	
that	 of	 T-cap	 (phase	 CT23.0)	 (Apendix	 File	 8).	 	 We	 predict	Murf1	 levels	 to	 be	
highest	 at	 the	 end	 of	 the	 active-phase.	 	 During	 the	 inactive-phase,	 in	 addition	 to	
lower	 transcript	 levels	caused	by	a	decrease	 in	BMAL1:CLOCK	transactivation,	 the	
skeletal	muscle	 	may	also	more	readily	target	T-CAP	for	degradation	by	MURF1	to	
keep	T-CAP	protein	levels	low	during	this	time	period.		Additional	experimentation	
is	 required	 to	 determine	 whether	 T-CAP	 is	 modified	 post-translationally,	 or	
degraded	in	a	circadian	manner	as	these	experiments	are	outside	the	scope	of	this	
dissertation.	
	
3.3.3 T-cap’s	expression	and	circadian	oscillation	are	dampened	in	iMS-Bmal1-/-	
muscle	tissue	
The	 iMS-Bmal1-/-	 transcriptome	 analysis	 (section	 2.3.4)	 revealed	 large-scale	
disruptions	 of	 the	 circadian	 transcripts.	 BMAL1,	 together	 with	 CLOCK/NPAS2,	
function	 as	 the	 positive	 limb	 of	 the	 molecular-clock.[7]	 To	 determine	 if	 T-CAP	
protein	was	also	reduced	 in	the	 iMS-Bmal1-/-,	we	compared	protein	expression	via	
western-blot	of	muscle	extracts	from	iMS-Bmal1+/+	and	iMS-Bmal1-/-	muscle	tissue	at	
CT2	and	CT14	(n=8	per	treatment	and	time-point).		These	times	were	chosen	based	
on	the	temporal	gene	expression	pattern	of	T-cap	as	CT2	represents	2	hours	into	the	
inactive-phase	when	mRNA	expression	is	dampening,	while	CT14	is	2	hours	into	the	
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active-phase	when	mRNA	expression	is	highest.		Overall	T-CAP	protein	was	greatly	
diminished	in	iMS-Bmal1-/-	muscle	tissue	as	to	be	expected	from	the	real-time	PCR	
results	 (Figure	17).	 	These	 results	 further	argue	 that	T-CAP	protein	expression	 is	
regulated	by	the	relative	amounts	of	T-cap	mRNA	present	within	the	cell.			
	
		
3.3.3.1 T-cap:luciferase	oscillates	in	an	anti-phasic	manner	to	Bmal1:luciferase	in	
vitro			
It	 is	 widely	 known	 that	 the	 timing	 of	 the	 molecular-clock	 can	 be	 influenced	 by	
numerous	 environmental	 time-cues	 (Zietgeibers).[49]	 For	 instance,	 the	 skeletal	
muscle	 clock	 phase-shifts	 in	 response	 to	 external	 time-cues,	 such	 as	 time	 of	
exercise.[73]	 External	 environmental	 stimuli	 and	 downstream	 cell-signaling	
cascades	 can	also	 influence	gene	expression	 in	 the	absence	of	 the	molecular-clock	
mechanism.		In	this	manner	it	is	possible	for	genes	to	oscillate	in	a	circadian	manner	
without	being	directly	regulated	by	the	molecular	clock.		The	observation	that	T-cap	
mRNA	and	protein	oscillates	in	a	circadian	manner	in	skeletal	muscle	suggests	that	
it	 is	 regulated	 downstream	 of	 the	 endogenous	 molecular	 clock,	 but	 the	 in	 vivo	
setting	in	which	these	assays	were	performed	raises	the	possibilities	of	confounding	
factors	 such	 as	 eating	 or	 activity	 patterns	 (both	 highly	 circadian	 in	 nature)	
potentially	 influencing	 the	T-cap	 circadian	oscillation.	 	 In	order	 to	 account	 for	 the	
presence	of	such	confounding	factors	we	decided	to	assay	the	circadian	rhythmicity	
of	T-cap	 in	an	 in	vitro	environment	null	of	external	time-cues.	 	For	our	analysis	we	
choose	 to	 record	 T-cap	 promoter:reporter	 luciferase	 bioluminescence	 in	
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synchronized	 C2C12	 myotubes	 over	 multiple	 circadian	 cycles.	 	 The	 T-cap	
promoter:reporter	 construct	 we	 utilized	 in	 our	 study	 consists	 of	 a	 421	 base-pair	
proximal-promoter	 region	 cloned	 upstream	 of	 Firefly	 luciferase	 gene	 (Appendix	
File	 10).	 	 	 To	 detect	 T-cap	 biolumenesnce	 we	 used	 a	 Lumicycle	 incubator	
(Actimetrix),	 as	 this	 is	 a	 powerful	 tool	 for	 measuring	 multiple	 parameters	 of	
circadian	 rhythmicity	 (period	 length,	 amplitude,	 acrophase),	 because	 it	 allows	 for	
the	 recording	 of	 bioluminescence	 for	 successive	 days	 with	 high	 temporal	
resolution.[221]	 We	 observed	 a	 robust	 circadian	 oscillation	 of	 T-cap:luciferase	
activity	 with	 an	 approximate	 22	 to	 24	 hour	 period	 length	 in	 C2C12	 myotubes	
(Figure	 18).	 	 Furthermore,	 the	T-cap:luciferase	 circadian	 pattern	 is	 antiphasic	 to	
that	of	Bmal1:luciferase	activity	in	C2C12	myotubes	synchronized	at	the	same	time.		
The	observation	that	the	T-cap:Luciferase	reporter	displays	a	circadian	oscillation	in	
C2C12	myotubes	indicates	that	the	T-cap	promoter	contains	the	essential	elements	
necessary	 for	 downstream	 regulation	 by	 the	 endogenous	 molecular-clock	 in	 the	
absence	of	external	 time-cues.	 	The	antiphasic	manner	 in	which	T-cap:luciferase	 is	
expressed	 in	vitro,	 in	 comparison	 to	Bmal1:luciferase,	 is	 very	 typical	 of	 a	CCG	and	
further	supports	 the	direct	 regulation	of	T-cap	by	 the	BMAL1:CLOCK	transcription	
factors.				
3.3.4 BMAL1:CLOCK	transactivate	T-cap:luciferase	activity	
The	significant	decreases	 in	T-cap	 expression	 in	 iMS-Bmal1-/-	muscle	 tissue	argues	
that	 T-cap	 is	 transcriptionally	 regulated	 down-stream	 of	 the	 clock,	 but	 does	 not	
discount	 the	 possibility	 that	 T-cap	 mRNA	 and	 protein	 are	 decreased	 due	 to	 an	
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Figure 18.  Representative graph of baseline subtracted Bmal1:luciferase 
(black circles) and T-cap:luciferase (red circles) over days in culture. Error 
bars denote SEM.  T-cap:luciferase-JTK_CYCLE: p-value 8.53E-9, period 22, 
relative phase CT1.  Bmal1:luciferase-JTK_CYCLE: p-value 2.12E-8, period 22, 
relative phase CT13.       
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alternative	mechanism.		For	instance,	T-cap	expression	could	dampen	in	response	to	
Bmal1	knockout	via	alternative	mechanisms	such	as	enhanced	mRNA	instability	or	
protein	 turnover	 since	we	 have	 observed	 the	 circadian	 oscillation	 of	 a	 number	 of	
genes	 that	 encode	 muscle	 specific	 E3-ubiquitin	 ligases.	 	 Therefore,	 we	 sought	 to	
determine	 if	 BMAL1:CLOCK	 transcriptionally	 activate	T-cap	 expression	 in	 skeletal	
muscle	 	 by	 performing	 a	 series	 of	 dual-reporter	 assays	 (Dual-Luciferase	 Reporter	
Assay	System,	Promega)	in	C2C12	muscle	cells	co-transfected	with	T-cap:Luciferase	
(reporter),	Renilla	luciferase	(control-reporter),	and	expression	plasmids	for	BMAL1	
and	 CLOCK.	 	 The	 dual-reporter	 system	 is	 commonly	 used	 to	 accurately	 quantify	
transactivation	of	promoter-reporter	constructs.	 	Overexpression	of	the	molecular-
clock	 factors,	 BMAL1:CLOCK,	 appeared	 to	 drive	 a	 slight	 increase	T-cap:Luciferase	
activity	(~2-fold)	in	C2C12	myotubes	(Figure	19).	 	A	possible	explanation	for	why	
BMAL1:CLOCK	 do	 not	 drive	 a	 robust	 increase	 in	T-cap:Luciferase	 activity,	 is	 that	
additional	 factor(s)	 are	 required	 to	promote	T-cap	 expression	 in	 skeletal	muscle	 .		
Interestingly,	we	observed	no	apparent	 increase	 in	T-cap:Luciferase	activity	when	
we	over-expressed	a	mutant	form	of	BMAL1	that	contains	an	A91G	point	mutation	
rendering	the	protein	incapable	of	binding	DNA	(Figure	19).	
3.3.5 MYOD1	works	in	a	synergistic	fashion	with	BMAL1:CLOCK	to	drive	T-cap	
expression	
Zhang	 et	al.	 have	 previously	 shown	 that	 the	T-cap	promoter	 is	 responsive	 to	 the	
muscle	specific	transcription	factor	MYOD1	in	NIH-3T3	fibroblasts.[99]	Additionally,	
this	group	suggests	that	MYOD1	plays	a	role	in	promoting	T-cap	expression	during	
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Figure 19.  Dual-luciferase results for T-cap:luciferase  reporter co-transfect-
ed with expression plasmids for BMAL1 and CLOCK, or BMAL1-R91A mutant 
and CLOCK normalized to the empty vector control. n=3/sample.  
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development	 as	 they	demonstrated	MYOD1	binding	 to	 the	T-cap	 promoter	during	
embryogenesis.[99]	We	observed	a	5-fold	induction	of	T-cap:luciferase	activity	with	
transient	transfection	of	MYOD1	in	C2C12	myotubes	compared	to	the	empty	vector	
pGL3	 control	 (Figure	 20).	 	 The	 MYOD1	 protein	 contains	 multiple	 domains	 that	
function	 to	 promote	 gene	 expression	 in	 several	 ways.[222]	 MYOD1	 contains	 a	
transactivting	 domain	 (TAD)	 involved	 in	 protein:protein	 interactions	 that	 recruit	
transcriptional	 machinery	 and	 other	 transcription	 factors	 to	 myogenic	 promoter	
regions.[223,	224]	 	MYOD1	also	 contains	 two	chromatin	 remodeling	domains	 that	
recruit	 histone	 acetylases	 to	 promote	 euchromatin	 formation	 to	 allow	 additional	
transcription	 factors	 to	 more	 readily	 access	 the	 DNA.[225]	 To	 determine	 the	
functional	importance	of	MYOD1’s	TAD	in	regulating	T-cap	expression	we	repeated	
the	dual-luciferase	 assay	with	 a	MYOD1	mutant	 expression	plasmid,	Myod1-3Δ56,	
that	 lacks	 the	TAD.[224]	We	observed	no	enhancement	of	T-cap:luciferase	activity	
with	 overexpression	 of	 Myod1-3Δ56,	 and	 luciferase	 activity	 appeared	 to	 be	
dampened	below	that	of	the	control	levels	(Figure	20).	 	These	results	suggest	that	
the	MYOD1	mutant	may	be	acting	in	a	dominate-negative	fashion,	where	it	may	be	
out-competing	endogenous	MYOD1	for	the	T-cap	promoter.				
To	test	whether	MYOD1	is	required	for	BMAL1:CLOCK	mediated	transactivation	of	
T-cap	we	measured	T-cap:luciferase	activity	in	C2C12	myotubes	co-transfected	with	
MYOD1	 and	 BMAL1:CLOCK.	 Interestingly,	 over-expression	 of	 MYOD1	 with	
BMAL1:CLOCK	resulted	in	a	~20	fold	induction	of	T-cap:luciferase	activity	(Figure	
21),	 which	 is	 approximately	 10	 fold	 higher	 than	 BMAL1:CLOCK	 over-expression	
alone.	 	These	data	 indicate	 that	MYOD1	and	 the	molecular-clock	 factors	work	 in	a	
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Figure 20.  Dual-luciferase results for T-cap:luciferase reporter co-transfect-
ed with expression plasmids for MYOD1 and MYOD1-3Δ56 mutant normal-
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Figure 21.  Dual-luciferase results for T-cap:luciferase reporter co-transfect-
ed with expression plasmids for MYOD1+BMAL1+CLOCK, MYOD1+B-
MAL1-R91A mutant+CLOCK, and MYOD1-3Δ56 mutant+BMAL1+CLOCK 
normalized to the empty vector control. n=3/sample  ***P ≤ 0.001 compared 
to empty vector control.    
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synergistic	fashion	to	promote	T-cap	expression,	as	the	induction	of	T-cap:luciferase	
activity	is	much	greater	than	one	would	expect	if	the	interaction	was	additive.			The	
ability	of	BMAL1:CLOCK	to	transactivate	T-cap	was	abolished	with	over-expression	
of	 the	 mutant	 form	 of	 MYOD1	 (Figure	 21),	 suggesting	 that	 MYOD1	 function	 is	
required	for	the	molecular-clock	to	promote	T-cap	expression	in	skeletal	muscle	.		A	
number	of	possibilities	 exist	 that	would	help	explain	as	 to	why	T-cap	 oscillates	 in	
heart	 tissue	 in	 the	 absence	 of	MYOD1.	 	 It	 is	 possible	 that	 BMAL1:CLOCK	 interact	
with	 a	 heart-specific	 co-factor	 that	 is	 required	 for	 the	 expression	 of	T-cap	 in	 the	
heart	 such	 as	 the	 heart-specific	 bHLH	 transcription	 factors	 Hand1	 and	 Hand2.		
Another	 possibility	 is	 that	 skeletal	 muscle	 possesses	 a	 negative-regulator	 that	
suppresses	 the	 ability	 of	 BMAL1:CLOCK	 to	 transactivate	 T-cap	 expression	 in	 the	
absence	of	MYOD1.						
	
	
3.3.5.1 MYOD1	enhances	the	amplitude	of	the	T-cap:luciferase	oscillation		
To	further	explore	the	role	MYOD1	plays	in	regulating	the	circadian	expression	of	T-
cap	 we	 assayed	T-cap	 activity	 (lumicycle)	 for	 approximately	 4.5	 days	while	 over-
expressing	wild-type	or	mutant	MYOD1.		In	addition	to	enhancing	T-cap	expression,	
MYOD1	 over-expression	 promoted	 a	~10-fold	 increase	 in	 the	 amplitude	 of	 the	T-
cap:Luciferase	rhythm	(Figure	22A).		The	increases	in	the	amplitude	of	the	rhythm	
seemed	 to	 have	 little	 effect	 on	 period	 length	 or	 phase.	 	 We	 observed	 a	 marked	
decrease	 in	 the	 amplitude	of	 the	T-cap:Luciferase	 rhythm	with	over-expression	of	
MYOD1-3Δ56(Figure	 22B).	 	 Interestingly,	 the	 circadian	 pattern	 of	 the	 T-cap-
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Figure 22.  Representative graph of baseline subtracted T-cap:luciferase 
reporter values with co-transfection of MYOD1 (A) and MYOD1-3Δ56 (B). 
Error bars denote SEM.  Red circles indicate the co-transfected values.  The 
black circles represents T-cap:luciferase values with no co-transfection.  
T-cap:luciferase-JTK_CYCLE: p-value 2.07E-11, period 20, relative phase CT 
5.0.  T-cap:luciferase+MYOD1-JTK_CYCLE: p-value 2.87E-8, period 22, relative 
phase CT 3.0. T-cap:luciferase+MYOD1-3Δ56-JTK_CYCLE: p-value 8.09E-11, 
relative phase CT 2.0. 
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luciferase	 rhythm	 appeared	 to	 be	 unaltered	with	 over-expression	 of	 the	MYOD1-
3Δ56	construct,	 suggesting	 that	MYOD1	may	only	 regulate	 the	 transactivation	and	
amplitude	 of	 the	 T-cap	 oscillation	 while	 having	 minimal	 control	 on	 the	 actually	
timing	of	 the	rhythm.	 	MYOD1	protein	expression	peaks	 in	 the	mid-inactive	phase	
(~CT	 6.0),	 which	 is	 also	 approximately	 when	 BMAL1:CLOCK	 reaches	 peak	
transcriptional	activity.[66]	These	data	suggest	that	BMAL1:CLOCK	and	MYOD1	may	
transactivate	 genes	 during	 the	 inactive-phase	 to	 promote	 CCG	 expression	 to	 peak	
during	the	early	active-phase.		Further	temporal	binding	and	transcriptional	studies	
are	required	to	determine	 if	MYOD1	and	BMAL1:CLOCK	target	 the	same	promoter	
regions,	and	whether	they	bind	at	similar	times	through	the	day.						
	
	
	
3.3.6 BMAL1	and	MYOD1	bind	to	the	tandem	E-box	element	in	the	T-cap	promoter		
Two	E-box	elements	have	previously	been	identified	within	the	T-cap	promoter.[99]	
Zhang	 et	al.	 demonstrated	MYOD1	 binding	 on	 the	 proximal	 E-box	 element	 during	
embryogenesis,	 while	 Podobed	 et	 al.	 have	 shown	 BMAL1	 binding	 to	 the	 distal	
tandem	E-box	element	in	heart	tissue.[96]	We	performed	a	ChIP	assay	to	determine	
if	 both	 BMAL1	 and	 MYOD1	 bind	 to	 the	 T-cap	 promoter	 in	 C2C12	 myotubes.		
Compared	 to	 IgG	 control,	we	observed	an	8	 and	3-fold	 enrichment	of	BMAL1	and	
MYOD1	binding	on	the	distal	portion	of	the	T-cap	promoter	where	the	tandem	E-box	
element	 is	 located,	 respectively	 (Figure	 23A,	 B).	 	 While	 we	 did	 not	 detect	 any	
BMAL1	binding	on	the	proximal	portion	of	the	T-cap	promoter,	we	did	see	a	small	
82
IgG
Bm
al1
My
oD
1
Se
ru
m
0
1
2
3
Pe
rc
en
t o
f  I
np
ut
***
Tandem E-Box Element
**
IgG
Bm
al1
My
oD
1
Se
ru
m
0
20
40
60
Myogenin
Pe
rc
en
t o
f  I
np
ut
**
IgG
Bm
al1
My
oD
1
Se
ru
m
0
2
4
6
8
10
300
400
500
600
Pe
rc
en
t o
f  I
np
ut
Period 2
***
*
Inp
ut IgG
Bm
al1
My
oD
1
Tandem E-Box
PCR Product
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the T-cap promoter containing the tandem-E-Box element.  Real-time PCR 
results for IgG, BMAL1, MYOD1, and serum as percent of the Input values for 
binding to the tandem E-Box element (B), the Myogenin promoter (C), and the 
Period-2 promoter.  *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
A. B.
C. D.
83
amount	of	MYOD1	binding	(data	not	shown).		As	positive	controls	for	our	antibodies	
we	observed	binding	of	MYOD1	on	the	Myogenin	promoter,	and	BMAL1	binding	on	
the	Period-2	promoter	(Figure	23C,	D).			
3.3.6.1 The	tandem	E-box	in	the	T-cap	promoter	is	required	for	BMAL1:CLOCK	and	
MYOD1	transactivation	and	circadian	expression	pattern		
Due	to	the	observed	binding	of	both	BMAL1	and	MYOD1	within	the	region	of	distal	
promoter	 region	 containing	 the	 tandem	 E-box	 element,	 we	 aimed	 to	 identify	
whether	the	tandem	E-box	element	is	required	for	BMAL1:CLOCK/MYOD1	mediated	
transactivation	and/or	the	circadian	rhythmicity	of	T-cap.		To	this	end,	we	mutated	
the	5’-E-box	of	 the	 tandem	E-Box	element	of	 the	T-cap:luciferase	 reporter	by	site-
directed	 mutagenesis	 (CAGCAG	 to	 GTGCAG),	 and	 performed	 a	 series	 of	 dual-
reporter	and	lumicycle	assays.		The	mutated	T-cap	reporter	(denoted	as	T-mut)	was	
unresponsive	to	transactivation	by	over-expression	of	BMAL1:CLOCK,	MYOD1,	and	
BMAL1:CLOCK+MYOD1	compared	to	empty	vector	controls	(Figure	24).		The	T-mut	
reporter	 also	 displayed	 abnormal	 temporal	 expression	 patterns,	 and	 the	 MYOD1	
mediate	enhancement	of	the	amplitude	observed	for	the	wild-type	T-cap:luciferase	
reporter	was	 abolished	 (Figure	25A,	B).	 	 Along	with	 the	 ChIP	 studies,	 these	 data	
indicate	 that	 BMAL1:CLOCK	 and	MYOD1	 interact	with	 the	 tandem	 E-box	 element	
within	the	T-cap	promoter,	and	this	element	is	required	for	the	circadian	expression	
pattern	of	T-cap.			
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Figure 24.  Dual-luciferase results for the mutated T-cap:luciferase reporter 
co-transfected with expression plasmids for MYOD1, BMAL1+CLOCK, and 
MYOD1+BMAL1+CLOCK normalized to the empty vector control. n=2/sam-
ple.
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Figure 25.  Representative graph of baseline subtracted T-cap:luciferase 
(black) and Tmut:luciferase (red) reporter values  (A).  T-mut:luciferase 
reporter values co-transfected with MYOD1 (red) or no co-transfection 
(black)  (B). Error bars denote SEM.  T-cap:luciferase-JTK_CYCLE: p-value 
2.94E-16, period 20, relative phase CT12.  T-mut:luciferase-JTK_CYCLE: 
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3.3.7 MYOD1	and	BMAL1	do	not	form	a	protein:protein	interaction	in	C2C12	
myotubes	
The	 synergistic	 interaction	 of	 MYOD1	 and	 BMAL1:CLOCK,	 and	 the	 observed	
increases	 in	 the	 circadian	 amplitude	 of	 T-cap:luciferase	 with	 overexpression	 of	
MYOD1	suggests	 the	potential	 for	 these	 factors	 to	physically	 interact.	 	To	 test	 this	
potential	interaction	we	performed	a	series	of	co-immunoprecipitation	assays.		We	
first	 over-expressed	 either	 MYOD1	 or	 BMAL1	 fusion	 proteins	 contacting	 a	
hemaglutanin	tag	on	their	C-terminal	end	(MYOD1-HA,	BMAL1-HA).		We	then	pulled	
down	these	proteins	using	an	antibody	against	hemaglutanin	(IgG	was	used	as	the	
control	pull-down).	 	Western-blotting	 for	 either	BMAL1	 (bound	 to	MYOD1-HA)	or	
MYOD1	(bound	to	BMAL1-HA)	did	not	produce	sufficient	bands,	and	we	 therefore	
do	argue	that	these	factors	do	not	directly	dimerize	(Figure	26).			
3.3.8 Conclusion	
Here	we	report	the	identification	and	validation	of	T-cap	as	a	direct	clock-controlled	
gene	 in	 skeletal	 muscle.	 	 The	 temporal	 expression	 pattern	 of	 the	 T-CAP	 protein	
suggests	 that	 it	 is	most-highly	 expressed	 during	 the	 active	 phase	 of	 the	 circadian	
cycle.	 	 At	 this	 time,	 the	 potential	 functional	 consequences	 of	 rhythmic	 T-CAP	
expression	 are	 unknown,	 but	 the	 highly	 conserved	 E-box	 elements	 within	 its	
promoter	and	the	complex	nature	in	which	it	is	transcriptionally	regulated	suggests	
that	this	is	more	than	a	mere	vestigial	mechanism	in	skeletal	muscle.		The	novelty	of	
this	 study	 exists	 not	 so	 much	 in	 the	 identification	 of	 T-cap	 as	 a	 CCG,	 but	 in	 the	
observations	 that	 a	 muscle-specific	 transcription	 factor,	 MYOD1,	 can	 work	 in	 a	
synergistic	 nature	 with	 the	 molecular-clock	 to	 drive	 the	 expression	 of	 a	 muscle-
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Figure 26. Representative MYOD-HA and IgG CoIP (A) western-blot-
ting for BMAL1 and BMAL1-HA and IgG CoIP (B) western-blotting 
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specific	gene.	 	The	 fact	 that	T-cap	 is	 robustly	circadian	 in	heart-tissue,	which	does	
not	 express	 MYOD1,	 suggests	 the	 existence	 of	 an	 unknown	 heart-specific	
transcription	factor.		Additional	studies	are	required	to	fully	elucidate	the	molecular	
mechanisms	in	which	these	co-factors	work	together,	but	 it	 is	clear,	at-least	 in	our	
hands,	that	MYOD1	and	the	molecular-clock	factors	BMAL1:CLOCK	do	not	bind	in	a	
protein:protein	interaction.			
One	possible	mechanism	in	which	muscle-specific	genes	are	 targeted	 for	circadian	
oscillation	 is	 that	 MYOD1	 and/or	 BMAL1:CLOCK	 work	 as	 pioneering	 factors	 that	
recruit	chromatin	remodeling	enzymes	to	expose	binding	elements	within	promoter	
regions.	 	 Previous	 studies	 have	 shown	 the	 ability	 of	 BMAL1:CLOCK	 to	 recruit	
enzymes	 to	 the	DNA	to	promote	 the	rhythmic	opening	of	 the	chromatin	structure,	
and	thus	promote	the	rhythmic	binding	of	adjacent	transcription-factors.[226]	The	
demonstration	 that	 viral	 vectors	 undergo	 epigenetic	 changes	 and	 incorporate	
nucleosomes	 in	 a	 similar	 fashion	 to	 genomic	 DNA	 promotes	 the	 likelihood	 of	 the	
‘pioneering-factor’	hypothesis	 in	 the	explanation	of	our	 results	utilizing	 the	pGL3-
basic	luciferase	reporter.[227,	228]		Multiple	findings	in	our	current	study	support	
the	possibility	 that	BMAL1:CLOCK	are	 acting	 as	pioneering	 factors	 to	 regulate	 the	
rhythmic	binding	and/or	activation	of	MYOD1	to	promote	the	circadian	oscillation	
of	 muscle-specific	 genes.	 	 Most	 notably,	 the	 finding	 that	 over-expression	 of	 wild-
type	MYOD1	enhances	the	amplitude	of	the	T-cap	circadian	rhythm.		In	theory,	use	
of	 a	 viral-vector	 to	 over-express	MYOD1	 should	 result	 in	 a	 non-oscillating	 steady	
state	of	MYOD1	protein	at	all	circadian	time-points,	and	therefore	the	oscillation	of	
T-cap:luciferase	 activity	must	be	due	 to	 the	 circadian	oscillation	 in	BMAL1:CLOCK	
89
activity.	 	 This	 is	 further	 supported	 by	 the	 T-cap	 expression	 iMS-Bmal1-/-	muscle	
tissue	that	displays	a	very	low	and	non-oscillatory	expression	pattern.			Additionally,	
the	dual-reporter	assays	in	C2C12	muscle	cells,	and	the	fact	that	these	transcription	
factors	 bind	 at	 the	 same	 DNA	 motif,	 both	 highly	 suggest	 that	 MYOD1	 and	
BMAL1:CLOCK	work	as	co-activators,	possibly	in	a	larger	transcriptional	complex.				
	
4 Chapter	4:	Future	Directions	
4.1 Circadian	Regulation	of	Substrate	Metabolism	in	Skeletal	Muscle	
The	idea	that	metabolic	tissues	regulate	the	timing	of	anabolic	and	catabolic	
metabolism	is	not	novel,	nor	is	the	notion	that	the	molecular-clock	regulates	many	
metabolic	processes	throughout	the	body.		The	novelty	of	our	study	lies	in	our	
approach	to	identify	the	acrophase	(or	peak	expression)	of	metabolic	genes,	and	our	
observations	that	genes	encoding	rate-limiting	metabolic	enzymes	are	functionally	
clustered	in	time.		To	our	knowledge	we	are	the	first	to	utilize	JTK_CYCLE’s	ability	to	
accurately	identify	the	acrophase	of	circadian	genes	in	skeletal	muscle,	which	has	
allowed	us	to	make	predictions	about	how	the	molecular-clock	temporally	regulates	
substrate	metabolism.			From	our	results	we	would	predict	that	skeletal	muscle	is	
primed	for	lipid-oxidation	in	the	early	active	period,	carbohydrate	utilization	in	the	
mid-active	period,	and	glycogen	and	lipid	storage	toward	the	end	of	the	active	
phase.		Since	our	predictions	are	based	solely	on	transcript	level	data	we	require	a	
multitude	of	additional	studies	to	determine	if	the	circadian	metabolic	genes	we	
have	identified	are	rhythmic	at	the	protein-level	and	whether	this	translates	into	
varying	rates	of	substrate	utilization/storage	throughout	the	day.		One	global	
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approach	would	be	to	perform	a	time-course	metabolomics	study	in	wild-type	mice	
to	assay	substrate	levels	and	metabolic	rates	throughout	the	day.		Analysis	of	the	
gene	changes	in	the	iMS-Bmal1-/-	skeletal	muscle	has	provided	clues	as	to	what	
metabolic	genes	are	downstream	of	the	molecular	clock.		We	predict	that	
BMAL1:CLOCK	target	genes	involved	in	catabolic	processes	to	be	expressed	during	
the	early	active	period,	while	we	predict	REV-ERB’s	to	target	genes	involved	in	
anabolic	processes	to	be	repressed	during	the	active	period.		A	time-course	ChIP-
Seq	analysis	of	wild-type	skeletal	muscle	probing	for	both	BMAL1	and	REV-ERBα	
would	help	to	elucidate	target	genes,	as	well	as	a	temporal	landscape	of	binding.	
	
4.2 Muscle	Specific	Regulation	of	Clock-Controlled	Genes		
The	observation	that	the	molecular-clock	directly	targets	the	z-line	protein	T-cap	
suggests	a	novel	mechanism	whereby	the	maintenance	of	myofibrillar	structure,	and	
thus	muscle	function,	are	temporally	regulated.		The	protein	expression	profile	of	T-
CAP	suggests	that	this	molecule	reaches	peak	levels	during	the	mid-	to	late-active	
phase.		One	possible	explanation	for	the	functional	importance	of	the	temporal	
expression	profile	of	T-CAP	is	to	add	or	subtract	stability	to	the	myofibrils	in	
relation	to	the	amount	of	stress	the	muscle	will	experience.		In	effect,	having	high	
levels	of	T-CAP	at	the	z-line	could	provide	more	stability	and	rigidity	to	the	
myofibrils	during	the	active	period	when	the	demand	on	skeletal	muscle	is	high.		
Since	skeletal	muscle	is	in	a	state	of	partial	paralysis	during	sleep	this	period	
coincides	with	a	decreased	demand	for	the	muscle.		During	the	inactive	period	low	
T-CAP	levels	could	result	in	a	partial	relaxation	of	the	myofibrils.		It	is	possible	that	
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repair	mechanisms	are	under	temporal	regulation	and	the	inactive	phase	may	be	an	
optimal	time	to	repair/reorganize	the	structural	components	within	muscle.		The	
observations	that	Murf1	mRNA	is	highly	circadian	and	peaks	just	prior	to	the	
inactive	period	further	supports	the	possibility	that	sarcomeric	proteins	are	
targeted	for	proteasomal	degradation	during	the	inactive	period.		As	myofibrillar	
proteins	turnover,	the	presence	of	a	partially	relaxed	structure	may	facilitate	the	
incorporation	of	newly	translated	proteins	and	sarcomeric	units.		T-cap	has	also	
been	shown	to	interact	with	multiple	t-tubule	proteins	to	direct	the	localization	of	
the	neuromuscular	junction	to	the	z-line.		Therefore,	the	functional	importance	of	
the	T-CAP	oscillation	in	muscle	may	also	be	to	promote	a	time	of	day	sensitivity	for	
excitation-contraction	coupling	as	well	as	calcium	induced	intracellular	signaling	
and	mechanotransduction.	
We	have	provided	evidence	that	the	molecular-clock	factors	BMAL1:CLOCK	work	in	
a	synergistic	fashion	with	the	myogenic	regulatory	factor	MYOD1	to	promote	the	
circadian	expression	of	the	muscle-specific	gene	T-cap.		The	findings	in	this	study	
provoke	numerous	questions	regarding	the	interaction	of	MYOD1	with	
BMAL1:CLOCK.		Firstly,	is	this	interaction	specific	to	T-cap	or	do	MYOD1	and	
BMAL1:CLOCK	target	the	majority	of	muscle-specific	circadian	genes?		Our	lab	is	
actively	pursuing	these	questions	by	performing	a	time-course	ChIP-Seq	analysis	for	
BMAL1	and	MYOD1.		These	experiments	will	allow	us	to	determine	whether	
BMAL1:CLOCK	and	MYOD1	target	the	same	circadian	genes,	and	will	also	allow	us	to	
quantify	the	extent	of	binding	over	time	of	day.		This	may	provide	clues	as	to	how	
these	factors	are	working.		For	instance	we	may	be	able	to	predict	if	BMAL1:CLOCK	
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or	MYOD1	work	as	pioneering	factors	by	determining	which	factors	bind	to	the	
promoter	regions	first.		We	have	demonstrated	that	the	tandem-E-Box	element	
within	the	proximal	promoter	of	T-cap	appears	to	be	the	primary	binding	site	for	
BMAL1:CLOCK	and	MYOD1,	and	that	it	is	absolutely	essential	for	the	circadian	
expression	of	T-cap.		Using	the	ChIP-Seq	data	as	a	guide	we	could	perform	a	
bioinformatics	study	in	which	we	examine	the	promoters	of	muscle-specific	genes	to	
determine	if	the	tandem-E-Box	elements	are	essential	for	BMAL1:CLOCK	and	
MYOD1	cooperatively.		We	provided	evidence	that	MYOD1	function	is	required	for	
the	ability	of	BMAL1:CLOCK	to	drive	T-cap	expression	(mutant	MYOD1	assays).		
Additional	studies	are	required	to	determine	if	other	myogenic	regulatory	factors,	
such	as	MYOGENIN,	can	be	substituted	for	MYOD1	and	still	promote	the	circadian	
oscillation	of	T-cap.	
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5	Chapter	5:	Dissertation	summary	
	
Through	the	use	of	high-resolution	time-course	microarray	data	we	were	able	to	
identify	a	significantly	large	number	of	genes	expressed	in	a	circadian	manner	in	
skeletal	muscle.	Utilizing	the	circadian	statistical	algorithm,	JTK_CYCLE,	we	were	
able	to	accurately	identify	the	acrophase	of	metabolic	genes,	which	resulted	in	the	
observations	that	catabolic	and	anabolic	metabolic	processes	are	temporally	
segregated	in	skeletal	muscle.		Our	data	suggests	that	skeletal	muscle	prefers	lipid	
oxidation	in	the	inactive	and	early	active-phase	(morning)	prior	to	that	of	
carbohydrate	breakdown.		In	addition	to	rate-limiting	enzymes	we	also	identified	
multiple	genes	that	encode	for	activators/repressors	of	substrate	metabolism	(Pdk4,	
Pdp1,	Nrip1,	etc).		In	this	manner	the	molecular-clock	controls	the	temporal	
expression	of	genes	that	act	as	molecular	switches,	so	metabolic	processes	are	
always	followed	by	a	break	to	the	system.		These	mechanisms	help	to	promote	the	
precise	temporal	control	of	substrate	preference	or	the	capacity	of	the	muscle	to	
store	over	use,	or	vice-versa.		The	observation	that	there	is	a	switch	toward	a	more	
oxidative	state	in	iMS-Bmal1-/-	skeletal	muscle	with	a	decrease	in	genes	involved	in	
carbohydrate	metabolism	strongly	suggests	that	the	molecular-clock	is	vitally	
important	in	controlling	the	timing	of	carbohydrate	metabolism.		Since	skeletal	
muscle	is	the	main	site	for	post-prandial	glucose	uptake,	understanding	how	the	
molecular	clock	regulates	carbohydrate	uptake,	storage,	and	breakdown	can	be	a	
potential	new	focus	for	understanding	diseases	such	as	diabetes,	obesity,	and	
metabolic	syndrome.		
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It	is	becoming	increasingly	evident	that	the	mechanisms	in	which	the	molecular-
clock	regulates	the	precise	timing	is	not	only	highly-complex,	but	diverse	over	
different	cell	types.		Herein	we	provide	evidence	that	the	molecular-clock	and	the	
myogenic	regulatory	factor,	MYOD1,	work	in	a	synergistic	fashion	to	promote	the	
expression	of	a	muscle-specific	gene.		These	factors	not	only	target	the	same	
promoter	element,	but	seem	to	work	as	co-factors	that	require	each	other’s	
presence	to	promote	circadian	rhythmicity.		Future	experiments	are	needed	to	
determine	if	the	molecular-clock	works	with	other	myogenic	regulatory	factors,	and	
whether	these	factors	changes	throughout	the	development	and	maturation	of	
skeletal	muscle.		We	propose	that	the	molecular	clock	may	be	interacting	with	many	
different	tissue-specific	factors	to	promote	circadian	output	in	a	tissue	dependent	
manner.		Identifying	such	factors	may	result	in	the	identification	of	drug-able	targets	
for	entraining	the	molecular-clock	or	promoting	molecular-clock	output.			
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Appendix File 1. Normalized gene expression traces of circadian lipid 
metabolic genes. Normalized expression traces of the circadian metabolic 
genes from the high-resolution skeletal muscle time-course transcriptome 
(data were downloaded from NCBI GEO datasets-GSE54652). Grey bars 
indicated the active period and white bars indicate the inactive period. Note 
that mice were in constant darkness during the time-course collection. Red 
lines indicate the acrophase (time of peak expression) calculated by JTK_CY-
CLE algorithm. A 6° polynomial was fit to the data to highlight the tempo-ral 
expression pattern (black line). 
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Appendix File 2. Normalized gene expression traces of circadian lipid 
metabolic genes. Normalized expression traces of the circadian metabolic 
genes from the high-resolution skeletal muscle time-course transcriptome 
(data were downloaded from NCBI GEO datasets-GSE54652). Grey bars 
indicated the active period and white bars indicate the inactive period. Note 
that mice were in constant darkness during the time-course collection. Red 
lines indicate the acrophase (time of peak expression) calculated by JTK_CY-
CLE algorithm. A 6° polynomial was fit to the data to highlight the tempo-ral 
expression pattern (black line). 
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Appendix File 3. Normalized gene expression traces of circadian glycolytic 
metabolic genes. Normalized expression traces of the circadian metabolic 
genes from the high-resolution skeletal muscle time-course transcriptome 
(data were downloaded from NCBI GEO datasets-GSE54652). Grey bars 
indicated the active period and white bars indicate the inactive period. Note 
that mice were in constant darkness during the time-course collection. Red 
lines indicate the acrophase (time of peak expression) calculated by 
JTK_CYCLE algorithm. A 6° polynomial was fit to the data to highlight the 
temporal expression pattern (black line). 
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Appendix File 4. Normalized gene expression traces of circadian glycolytic 
metabolic genes. Normalized expression traces of the circadian metabolic 
genes from the high-resolution skeletal muscle time-course transcriptome 
(data were downloaded from NCBI GEO datasets-GSE54652). Grey bars 
indicated the active period and white bars indicate the inactive period. Note 
that mice were in constant darkness during the time-course collection. Red 
lines indicate the acrophase (time of peak expression) calculated by 
JTK_CYCLE algorithm. A 6° polynomial was �it to the data to highlight the 
temporal expression pattern (black line). 
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Appendix File 5. Temporal gene expression traces of circadian metabolic 
genes. Gene expression traces for circadian metabolic genes from the Mouse 
ST 1.0 Affymetrix gene array for gastrocnemius tissue collected at circadian 
times 18 to 38. iMS-Bmal1+/+ control values are indicated as black 
diamonds and iMS-Bmal1−/− are indicated as red squares. Grey bars 
indicat-ed the active period, and white bars indicate the inactive period. 
Note that mice were in constant darkness during the time-course collection.
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Real-time PCR results for circadian metabolic genes. Real-time PCR 
results (C) of time-course expression values for Fabp3, Pnpla3, Hk2, 
and Pdp1 in the iMS-Bmal1+/+ (black) and iMS-Bmal1−/− (red). Paired 
t test of Fabp3 (P value = 0.02), Pnpla3 (P value = 0.4), Hk2 (P value = 
0.001), and Pdp1 (P value = 0.15).
Appendix File 6.  Real-time PCR results for circadian metabolic 
genes. Real-time PCR results of time-course expression values for 
Fabp3, Pnpla3, Hk2, and Pdp1 in the iMS-Bmal1+/+ (black) and 
iMS-Bmal1−/− (red). Paired t test of Fabp3 (P value = 0.02), 
Pnpla3 (P value = 0.4), Hk2 (P value = 0.001), and Pdp1 (P value = 
0.15).
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Appendix File 7. Temporal gene expression traces of the core moleclar-clock 
genes. Gene expression traces are from the Mouse ST 1.0 Affymetrix gene 
array for gastrocnemius tissue collected at circadian times 18 to 38. 
iMS-Bmal1+/+ control values are indicated as black diamonds and iMS-Bmal1
−/− are indicated as red squares. Grey bars indicated the active period, and 
white bars indicate the inactive period. Note that mice were in constant 
darkness during the time-course collection.
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Appendix File 8. Temporal expression pattern of T-cap and Murf1 from 
the Hogenesch skeletal muscle circadian transcriptome.  The circles 
represent the expression values of T-cap at each circadian 
time-point.  The dotted line is a 6-degree polynomial �itted to the expres-
sion data.  Grey bars indicated the active period, and white bars indicate 
the inactive period. Note that mice were in constant darkness during the 
time-course collection.
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Appendix File 9.  Western-blots of iMS-Bmal1+/+ and iMS-Bmal1-/- 
gastrocnemius tissue for T-CAP and gamma-Tubulin control at CT2 (top) and 
CT14 (bottom).  First lane of the left is the protein ladder, top band is 50KDa 
and the bottom band is 20KDa.
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Appendix File 10. T-cap proximal promoter sequence. The letters inside the 
parenthesis indicate the nucleotides following site directed mutagenesis.  The 
tandem E-box element is highlighted red, proximal E-box element is highlighted 
green:
5’- 
GAGGGCATCAGTTCCTGCTTCTCCTGTTCTGTTTACAGACAAGCTGCTGTCCTCCCTGAGC
AAGGGGGGAGCAGAGGAAGACAGTGCCAAGGTGGC(G)A(T)C(G)G(C)AGGCTGCCCATG
TGCCTGGTCCGAGGTGGTGTTTGCAGCATGCCAGACACCCAGAGGTGCTACTCTGAGAAC
CCAGGTCCCCAACAGAGCATCTTGCAGGCTTTGAAAGCTGACCTCTGACCTGGGAGCAAC
CAGAATCTGGGTACCCCAACCCCCGCCCCGGACTCAGAGCCCCATCACCACCAGTGAGTCT
TGGCTCTGCTTATAGCATCTGACGCCAGAGGGGCTGAAAATAGCCCCTGGAGAAGGGGG
AGAGGGGGAAGAAGGGGCTATTTAAAGGGCTCTGGAGGAGCAGGACATAGCAGAGGGAG
CAATCAGAAATCAGATCTGCGATCTAAGTAAGCTTGGCATTCCGGTACTGTTGGTAAAGC
CACCATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTATCCGCTGGAAGA
TGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGCCCTGGTTCCTGGAAC
AATTGCTTTTACAGATGCACATATCGAGGTGGACATCACTTACGCTGAGTACTTCGAAAT
GTCCGTTCGGTTGGCAGAAGCTATGAAACGATATGGGCT GAATACAAATCA-3’!
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